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Abstract 
 
This thesis collects the work I have done during the three-year PhD Course. During my first 
year I have started a path that has allowed me to acquire different techniques devoted to set up 
and maintain primary cell cultures and cancer derived cell lines as well as to evaluate the 
cytotoxicity of potential novel synthetic inhibitors of human cancer cells. Part of the second and 
all the third year was spent at the University of Cape Town, South Africa, in the laboratory of 
prof. Ariel Katz under the supervision of proff. Roger Hunter and Catherine H. Kaschula 
investigating the anticancer activity of Z-ajoene, a garlic compound.  
 
Overall, the main aim of all the my research project was to identify and characterize natural or 
synthetic compounds as new antineoplastic agents. The results obtained are divided according 
to the research topics addressed: 
 Anticancer activity of new Phenanthroline compounds (Part I); 
 The garlic compound Z-ajoene as anticancer agents (Part II). 
 
Studies referring to the Part have been carried out at the University of Cagliari and were 
focalized on the evaluation of new Cu(II) -phenanthroline complexes as a potent antineoplastic 
agents against various solid and suspension tumours. The [Cu(1,10-phenanthrolin 
-5,6-diol)2(OH2)](ClO4)2 complex appears to be the most potent compound against human 
leukemia, prostate and lung cancer cell lines. The results obtained on the biological activity of 
this class of compounds, providing valuable information for the design of new anticancer drugs, 
have been published in the Journal of Inorganic Biochemistry (2014).  
 
As for the Part II of my research, I focused on the mechanisms underlying the anti-tumoral 
activity of garlic compound Z-ajoene on human triple –negative breast cancer cells. The results 
indicate that Z-ajoene localizes in the ER of MDA-MB-231 cells where it activates the unfolded 
protein response (UPR) and ER stress. These findings have been published in the Molecular 
Carcinogenesis journal (2015)  
 
Moreover, immunofluorescence studies support the concept that the Z-ajoene main target is a 
ER-resident chaperon protein (PDI), whose functional alteration may well be the cause of the 
cytotoxic effect. Another molecular target of Z-ajoene is the cytoskeleton protein Vimentin. 
Z-ajoene interacts with Vimentin through a S–thiolation causing the disruption of Vimentin 
filaments and therefore an alteration of the cell morphology. Given that Vimentin is known to 
participate to the early stage of the metastatic process, I also investigated the potential effect of 
Z-ajoene at non-cytotoxic concentrations in a specific cell assay and found that it effectively 
inhibits cell migration, both in the absence and presence of a chemotactic agent. The metastatic 
inhibition induced by Z-ajoene seems caused by modification of several signaling pathways as 
expression of Axl and Src proteins, and phosphorylation of β–catenin were changed. Although 
following inhibition of cell migration, a reduction of Vimentin expression was to be expected, 
Z-ajoene treatment surprisingly induced an upregulation of Vimentin. We interpreted this result 
as a consequence of Z-ajoene binding to Vimentin which unable this protein to perform its 
physiologic functions (manuscripts in preparation). 
 
Altogether, the data of my in vitro study indicate that Z-ajoene is a promising chemotherapeutic 
agent simultaneously acting on different molecular targets, also able to affect the metastatic 
process in cells derived from highly invasive breast tumors. Due to its potential use in the clinic,  
preclinical evaluation in xenograft mouse models of cancer are ongoing.   
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Part I - Anticancer activity of new Phenanthroline compounds  
 
Chapter I - Novel copper(II) complexes as new promising antitumour 
agents.  
 
The first part of my research has focused on the study of anti-tumour effects carried out by a 
new class of compounds, the Copper(II) complexes with 1,10-phenanthroline derivatives.  
 
Copper is a metal ion essential for aerobic microorganisms, plants and animals. It binds 
molecular oxygen in oxygen-transport proteins and participates in electron transport 
[Terwilliger N. B., J. Exp. Biol. 1998]. In the human body the copper concentration level is 
regulated by the homeostatic system. Copper has been selected for the synthesis of new 
antitumour drugs since complexes containing essential metal ions, thanks to the homeostatic 
regulatory system, may produce less systemic toxicity than complexes with exogenous metal 
ions. 
Copper(II) complexes with nitrogen ligands such as 1,10-phenanthroline (phen) show 
cytotoxic activity against a panel of human tumour cell lines.[T. Pivetta et al J. Inorg. 
Biochem. 2012; T. Pivetta et al.; Talanta 2013]. 
Ternary complexes of 1,10-phenanthroline-5,6-dione (phendione) with copper(II) show 
interesting cytotoxic activity against human kidney adenocarcinoma and human 
hepatocellular carcinoma cell lines. [3] Many other phen derivatives, alone or in complexes, 
have been tested for antitumour activity towards human ovarian carcinoma, melanoma and 
breast, colon, ovarian, renal and non-small-cell lung cancer. [S. Roy et al. Chem Med Chem, 
2008; S. Betanzos-Lara et al., J. Biol. Inorg. Chem. 2012; A. N. Wein et al., J. Inorg. 
Biochem. 2011]. 
On this basis, we decided to study the differences in chemical behavior and anti –
proliferative  activity of a new family of copper(II) complexes with phendione and 
1,10-phenanthroline-5,6-diol (phendiol). Complexes with phen were also prepared and 
studied for comparison. 
 
The results of this study had already been published in the Journal of Inorganic Biochemistry 
(2014) attached below.  
Link at the published article: http://www.ncbi.nlm.nih.gov/pubmed/25238635. 
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Conclusions  
New copper(II) complexes with one or two 1,10-phenanthroline derivatives have been 
prepared. The studied ligands and complexes generally present a higher anti –
proliferative effect than that of cisplatin. The cytotoxic activity of the ligands was 
found to be correlated to the cellular microenvironment. Because the 
microenvironment of tumour cells is important for their carcinogenesis , the study of 
the interactions between microenvironment and drugs gives useful information for 
chemotherapeutic approaches. In this light, 1,10-phenanthrolin-5,6-diol appears 
among the three ligands, the most active on cells surrounded by a hydrophilic 
environment. Cu(II) complexes with one molecule of 1,10-phenanthroline, 
1,10-phenanthrolin-5,6-dione or 1,10- phenanthrolin-5,6-diol exhibited an anti –
proliferative activity lower than that of the ligand alone on all the tested cell lines. 
Complexes with two ligands are more cytotoxic towards all the tested cell lines than 
the related complexes with one ligand and are generally more cytotoxic than the ligand 
alone. 
The [Cu(1,10-phenanthrolin-5,6-diol)2(OH2)](ClO4)2 complex appears as the most 
active compound for the treatment of CCRF-CEM, CCRF-SB, SK-MES-1 and 
DU-145 human tumour cell lines. In particular this compound is very promising for 
the treatment of SK-MES-1, having a CC50 value 37 times lower than that of cisplatin. 
The [Cu(1,10-phenanthrolin-5,6-dione)2(OH2)(OClO3)](ClO4) complex is eligible for 
treatment of the HEP-G2 cell line, having a CC50 value 18 times lower than that of 
cisplatin. 
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Part II – The garlic compound as anticancer agents 
 
Introduction 
 
Garlic (Allium sativum L.) is a widely used medicinal plant with multiple beneficial 
effects against cardiovascular diseases, infections, and cancer [Wang Y et al. (2015) 
Tumour Biol. Oct.]. The sulfur –containing compounds, extracted from crushed garlic, 
are responsible for these beneficial health effects. These compounds include 
S-allylcysteine (SAC), S-allylmercaptocysteine (SAMC), diallyl sulfide (DAS), diallyl 
disulfide (DADS), diallyl trisulfide (DATS), diallyl tetrasulfide (DATTS), and the 
thiosulfinate allicin (Figure 1 below).  
Allicin is an unstable compound, but by its rearrangement may give rise a more stable 
compounds, including ajoene (E- and Z- 4,5,9- trithiadodeca-1,6,11-triene 9-oxide).  
 
 
Figure 1 : The major organosulfur compounds found in crushed garlic.  
Diallyl sulfide, diallyl disulfide, diallyl trisulfide, S-allylmercaptocysteine, S-allylcysteine E-ajoene, 
Z-ajoene and allicin. 
 
These garlic organosulfur compounds are all reported to be active at inhibiting the 
proliferation of tumour cells [Bayan L et al. (2014) Avicenna J Phytomed], although our 
work has centred predominantly on the anti-cancer activity of Z-ajoene . 
 
Z-ajoene (ZA) and the related garlic organosulfides all appear to induce apoptosis in 
cancer cells through the intrinsic pathway by activating the mitochondrial-dependent 
caspase cascade. In addition, Z-ajoene-induced apoptosis in these cells is reportedly 
accompanied by the generation of reactive oxygen species and the activation of nuclear 
factor kB [Dirsch, et al. (1998) Mol. Pharmacol]. Similar to other garlic-derived 
organosulfides, Z-ajoene is reported to arrest cells in the G2/M phase of the cell cycle 
[Capasso A. (2013) Molecules]. Although the downstream effects of Z-ajoene on cancer 
cells have been characterized, the specific Z-ajoene drug targets or early events leading to 
apoptosis are not known.  
Ajoene has been shown to inhibit proliferation of a number of different malignant cell 
lines, including breast and esophageal cancers [Kaschula C.H. et al. (2012) Eur. J. Med. 
Chem].  
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Chapter I – Studies on the mode of action of Z-ajoene. 
This chapter is divided into two sections: the first is entitled “The Garlic Compound 
Z-ajoene Targets Protein Folding in the Endoplasmic Reticulum of Cancer Cells” and 
we aimed to investigate about the mechanism by which the ajoene caused the 
cytotoxicity in cancer cells.  
The second section is entitled “Dansyl-ajoene (DP) colocalize with Protein Disulfide 
Isomerase (PDI) in the endoplasmic reticulum of human breast cancer cells” and we 
aimed to identify whether the PDI is a main target for anti-cancer activity of Ajoene.  
 
 
1.1 The garlic compound Z-ajoene targets protein folding in the 
endoplasmic reticulum of cancer cells 
 
In this chapter, we aimed to investigate about the mechanism by which the ajoene 
caused the cytotoxicity in breast and esophageal cancers. For this, two fluorescently 
labelled ajoene analogs with dansyl- (DP) and fluorescein- (FOX) tags were 
synthesized. 
 
We found that both DP and FOX inhibited the proliferation and induced apoptosis 
in human MDA-MB-231 breast and WHCO1 esophageal cancer cells. Both 
fluorescent ajoenes localized to the endoplasmic reticulum (ER) in MDA-MB-231 
cells. Here, DP interacted with multiple ER resident proteins by S-thiolation in 
MDA-MB-231 cells as observed by immunoblotting under non-reducing 
conditions only; and a competition assay demonstrated that DP and Z-ajoene in fact 
share the same target. In the ER, ajoene S-thiolation interfered with protein folding 
and led to an accumulation of misfolded protein aggregates and activated the 
unfolded protein response (UPR). Consistent with this mechanism, increased levels 
of GRP78 and total ubiquitinated proteins were observed. This is the first time that 
ajoene has been shown to target protein folding in the ER of cancer cells. 
 
The results of this study, that have been already published 
(http://onlinelibrary.wiley.com/doi/10.1002/mc.22364/full; license number 
3791820755606) in Molecular Carcinogenesis in 2015 are fully described below.  
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1.2 Dansyl-Ajoene (DP) co-localizes with Protein Disulfide 
Isomerase (PDI) in the endoplasmic reticulum of 
MDA-MB-231 breast cancer cells 
 
Introduction 
 
The background to this section is based on our previous work in which we found 
that ajoene S-thiolates many proteins in MDA-MB-231 cells [C. H. Kaschula et al. 
(2015) Mol Carcinog].  
 
In this study we found that the fluorescent ajoene analogue (dansyl-ajoene, DP) 
localizes to the endoplasmic reticulum (ER) in MDA-MB-231 breast cancer cells 
through the S-thiolation of ER resident proteins. We hypothesize that the 
ER-resident protein, Protein Disulfide Isomerase (PDI), may be an important  
ajoene target protein as it is an enzyme directly involved in the formation of 
disulfide bonds. 
 
PDI is a 57-kDa dithiol-disulfide oxidoreductase and molecular chaperone. It is 
found in the ER, nucleus, cytosol, mitochondria and cell membrane [Turano C. et 
al. (2002) J. Cell. Physiol.], and is one of the most abundant soluble proteins in the 
ER reaching near –millimolar concentrations and accounting for up to 0.8 % of the 
total cellular proteins in this organelle [Ferrari D.M. & Soling H.D. (1999) 
Biochem. J.]. 
 
Figure 2: Structure of PDI. (a) On the basis of various models of human PDI [Ferrari, D. et al.  
 
(1999) Biochem. J.; Freedman, R. et al. (2002) Embo Rep.] and the crystal structure of yeast PDI (S. 
cerevisiae, PDB ID code 2B5E) [Tian, G. et al. (2006) Cell], the structure of PDI consists of five 
domains and one linker organized in the order abb′xa′c. Residues are numbered according to mature 
human PDI (H. sapiens, SwissProt code P07237). Domains a (orange) and a′ (yellow) are 
homologous and contain the catalytic CxxC motif (green). Domains b (dark blue) and b′ (light blue) 
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are not homologous but adopt a same thioredoxin folding. The flexible linker region x (black) is 
located between domains b′ and a′ [Ferrari, D. et al. (1999) Biochem. J.]. The link between domains 
a and b is only one residue. The C-terminal extension (red) contains a (K/H)DEL retention signal for 
the ER. (b) Representation of the crystal structure of yeast PDI, which highlights the active-site 
cysteines in green. Colors of the domains are the same as in (a). [Gruber CW et al. (2006) Trends 
Biochem Sci.]. 
 
PDI is composed of 5 domains: a, a′, b, b′ and c and one linker domain x found 
between the a′ and b′ regions (Figure 2). Domains a and a′ are homologous, and 
each contain a catalytic Cys–X–X–Cys sequence which is involved in their redox 
and isomerization activities. Domains b and b′ do not have high sequence similarity 
but both adopt a thioredoxin folding tertiary structure; which is responsible for 
substrate binding [Okumura M. et al. (2015) Free Radical Biology and Medicine]. 
Depending on the redox state of a, PDI is subject to conformational rearrangement 
between the a and b domains and can assume an open or closed structure during its 
catalytic reaction (Figure 3) [Yagi-Utsumi M.et al. (2015) Sci Rep.]  
 
In fact, PDI is one of the most important enzymes of the ER, catalyzing disulfide 
bond formation (oxidase activity), rearrangement (isomerase activity) and 
reduction between cysteine residues in proteins and peptide substrates by mediating 
oxidative protein folding [B. Wilkinson & H. F. Gilbert (2004) Biochimica et 
Biophysica Acta (BBA)-Proteins and Proteomics,; R. Noiva & W. Lennarz, (1992) 
J. Biol. Chem.].  
 
 
Figure 3: Conformational structure of PDI. 
The PDI is subject to structural rearrangement depending on the reaction to be catalyzed (see above) 
[L. Wang et al. (2015) Free Radical Biology and Medicine] 
 
Increasing evidence suggests that PDI supports the survival and progression of 
several cancers [Xu S. et al. (2014) Drug Discovery Today]. It is reported that this 
protein is up-regulated in many tumors, including human multiple myeloma 
[Claudio JO et al. (2002) Blood], acute lymphoblastic leukemia (B cell), 
neuroblastoma, lung, colon, ovarian [Shin BK et al. (2003) J Biol Chem] and breast 
cancers [Updike MS et al. (2007) Anticancer Res; Persson S et al., (2005) Mol 
Phylogenet Evol.]. 
 
In this section, we aimed to verify whether PDI may be another target of the garlic 
compound ajoene. We therefore used fluorescence microscopy to determine 
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whether our fluorescent ajoene analogue DP and the protein PDI co-localize in 
MDA-MB-231 triple-negative breast cancer cells.  
 
Results and Discussion 
To investigate whether DP and PDI co–localize in MDA-MB-231 triple-negative 
breast cancer cells, immunofluorescence was performed. It was important to first 
select the correct concentration of DP which is not cytotoxic to MDA-MB-231 cells 
and is therefore not expected to affect the integrity of the cells. This was assessed 
by performing an MTT cell viability assay in MDA-MB-231 cells following 
treatment with 25 µM of DP for 6 hours as shown in Figure 4. We found that the 
values of cell viability of the treated samples were not different to those of the 
untreated control.  
 
 
Figure 4: Cytotoxicity of 25µM DP in MDA-MB-231 cells by MTT assay. 
Using an MTT cell viability assay, 25 µM DP was not found  to be cytotoxic to MDA-MB-231 
breast cancer cells after six hours of treatment. Control cells received 0.1 % DMSO (vehicle) alone. 
Data is expressed as a percentage of the mean ± SD of three independent experiments vs. untreated 
control. 
 
For immunohistochemistry, MDA-MB-231 cells were seeded on a glass cover-slip 
and treated with 25 µM DP for six hours. Thereafter, the cells were fixed and 
stained with the primary polyclonal PDI antibody and the cy-3 fluorescently-tagged 
secondary antibody. Cell sections were mounted on a glass slide for viewing under 
a confocal microscope. Under the microscope, DP emits blue fluorescence due to 
its fluorescent dansyl–group; whereas the PDI protein is detected in the red channel 
through a specific anti-PDI antibody. The treated samples are displayed in both 
channels (Blue and Red) to verify a possible co-localization of DP and PDI. 
 
We have previously found that ajoene localizes to the ER in MDA-MB-231 cells 
(Fig. 5-A). In the untreated cells (B), we found that PDI formed granular structures 
throughout the cytoplasm and concentrated at the level of the ER. 
In the DP-treated cells, we observed that the PDI signal, which is stained red (C), 
and DP, which fluoresces blue (E), co-localize strongly (F, pink stain) with each 
other in the cytoplasm of the MDA-MB-231 cells. The phase contrast images of the 
cells are also shown (D) as well as the co-localization map where strong 
co-localization is displayed This data suggests that most of the DP and PDI 
co-localize within the MDA-MB-231 cells.  
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The co-localization signal is displayed graphically by scatterplot. In this graph, the 
blue intensity is shown on the x-axis and the red intensity is shown on the y-axis. 
Four quadrants are designated with Black Zeiss Software, obtained through the 
exclusion of regions in which the intensity of the signal is low. Quadrants 1 
represent pixels with high blue intensity and low red intensity and Quadrant 2 
display pixels with high red intensity and low blue intensity. Quadrant 3 identified 
the pixels with high intensity for both channels and (blue and red), therefore in this 
region is observed the co-localization.  
 
Analyzing this scatterplot, we found that the DP signal is located in both quadrants 
1 and 3, suggesting that DP strongly co-localizes with PDI but that there are also 
regions in the cell in which PDI is not present. This result implies that DP may 
target PDI but that it may also have other protein targets within the MDA-MB-231 
cells. Interestingly, no red signal was detected in quadrant 2, suggesting that all of 
the PDI detected co-localized with DP (quadrant 3).  
 
The Black Zeiss Software provides several parameters including the Overlap 
Coefficient which indicates the degree of co-localization between the two channels, 
quantified according to the formula below (Figure 5 (i)): 
 
		
 
∑	1	2
∑	1	2	
 
 
The numerator measures pixels with significant intensity signals from both 
channels (red and blue) and is proportional to co-localized pixels; whereas the 
denominator quantifies all pixels with significant intensity values, regardless of 
co-localization. The values for the Overlap Coefficient range from 0 to 1, where 1 
represents perfectly co-localized pixels. 
Analyzing the data of 5 different images, we found that the average  Overlap 
Coefficient between DP and PDI is 0.4925 ± 0.09. Considering that DP acts on 
many other targets, this value of the overlap coefficient indicates an excellent level 
of co-localization between DP and PDI.  
 
Through co-localization examination, we can confirm that PDI is one of the main 
targets of dansyl–ajoene and that DP appears to saturate all the intracellular PDI 
(Figure 5, see quadrant 2 of scatterplot). 
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Figure 5: Co-localization between PDI and DP in MDA-MB-231 breast cancer cells. 
To determine whether Protein Disulfide Isomerase and ajoene co-localize in cancer 
cells, MDA-MB-231 cells were treated with the fluorescent dansyl-ajoene (DP), and 
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blue fluorescence was detected (A). All samples were also treated with the primary 
PDI antibody coupled to secondary Cy-3-antibody which fluoresces  red. In the 
untreated control (B), PDI was found to localize to the ER. The image of DP–treated 
cells shows that PDI (C) and DP (E) co-localize (F) in MDA-MB-231 cells. The 
phase contrast image is shown (D) and  signal co-localization is displayed with 
both the co-localization map (white signal) but also graphically by the scatterplot.  
(i) Table of parameters provided by the Black Zeiss Software relative to this image, 
including the Overlap Coefficient which indicates the degree of co-localization 
between DP and PDI protein. 
 
 
Conclusions 
We have previously found that ajoene targets and localizes in the ER of 
MDA-MB-231 cells, where it S–thiolates many proteins. This was found to activate 
the unfolded protein response (UPR) and ER stress which may be the modalities 
with which ajoene induces cytotoxicity in cancer cells. Based on our 
immunofluorescence findings, we propose that PDI may be one of the major 
protein targets of ajoene in the ER and that inhibition of PDI enzyme activity will 
inhibit the proper folding of proteins in the ER which may lead to activation of the 
unfolded protein response and ER stress by ajoene may cause the observed 
cytotoxic effects (Manuscript in preparation). 
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Chapter II – Vimentin as a target of Z-ajoene 
 
Introduction 
Vimentin, a 57 kDa cytoplasmic protein, is ubiquitously expressed in normal 
mesenchymal cells, and is a major constituent of the type III intermediate filament (IF) 
proteins, which forms a part of the cytoskeleton. [A. Satelli & S. Li (2011) Cell Mol Life 
Sci]. 
 
Figure 6: Molecular structure of Vimentin. 
The structure of Vimentin consists of a central rod domain, an N-terminal “head” domain, and a 
C-terminal “tail” domain. The head and tail domains consist of 77 and 61 residues, respectively. The 
central rod domain (328 residues) contains an α-helical region. These domains are separated by 3 linker 
regions referred to as L1, L12 and L2. [Dave JM and Bayless KJ. (2014) Microcirculation]. 
 
Different cytoplasmic proteins play a role in the transformation of a normal cell to an 
invasive tumor cell and among these, Vimentin is particularly important [ Calaf G.M. et 
al. (2014) Oncology Letters]. 
 
In recent years, Vimentin has been found to be a marker for epithelial-mesenchymal 
transition (EMT), a process in which epithelial cells lose characteristics that enable 
differentiation, including cell–cell adhesion, apical–basal polarity, and acquire a 
mesenchymal phenotype, characterized by motility, invasiveness and apoptotic 
resistance [A. Satelli & S. Li, (2011) Cell Mol Life Sci; Ye-Seul Kim et al (2014) 
Experimental & Molecular Medicine].  
 
Moreover, Vimentin is frequently over-expressed in neoplastic cells with metastatic 
properties, including breast cancer, prostate cancer, gastrointestinal tumors, CNS 
tumors, malignant melanoma, lung cancer and other types of tumors.  
 
In this chapter we aimed to firstly clone, express and purify recombinant Vimentin 
protein from E. coli in order to achieve the second aim which involved Investigating 
into the Role of Vimentin in the Anti-Cancer Activity of the Garlic Compound Ajoene.  
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2.1 Expression and purification of recombinant His-tagged 
Vimentin protein from E. Coli 
 
In this section, we aimed to clone Vimentin into a cloning/expression vector so as to 
have available large amounts of purified protein for further experiments.  
 
The South African team had already isolated Vimentin cDNA from MDA-MB-231 
breast cancer cells. Therefore the appropriate primers had already been identified 
for insertion of Vimentin into the cloning vector.  
 
Briefly, in order to start the experimental procedure, the Vimentin gene was 
amplified from cDNA (obtained from mRNA conversion) by PCR using specific 
Vimentin primers. The Vimentin fragment was then purified before it could be 
ligated into the Topo maintenance vector. During the transformation into Top10 
competent cells, the Topo vector with the ligated Vimentin gene entered the cells 
and only the cells that have incorporated the vector (which contained an ampicillin 
resistance gene) were able to grow in the presence of ampicillin and their insert 
would be cloned. Subsequently, the colonies that had taken up the Topo vector with 
the ligated Vimentin gene were screened, and colony PCR was carried out. Then, 
the plasmids were extracted and all clones with the correct sequence of Vimentin 
gene were identified by sequencing. 
 
Lastly, to express the final Vimentin protein, its coding sequence had to be 
transferred from the Topo maintenance vector into the pET-22b (+) 
cloning/expression vector. Both the Topo vector (which contained vimentin 
fragment) that the pET-22b (+) vector were subjected to a digestion analysis with 
Bam HI and Sal I RE, which allowed removal of the Vimentin sequence from the 
Topo vector followed by  insertion directly into the pET vector with ligation. 
During the transformation into BL 21 star DE3 competent cells, only the cells that 
had incorporated the pET-22b (+) vector with the ligated Vimentin gene were able 
to grow, then the colonies were screened, and colony PCR was carried out. Finally, 
the plasmids were extracted and all clones with the correct Vimentin sequence were 
identified by sequencing. 
 
Finally the clone with the correct Vimentin sequence grown so that Vimentin 
protein could be extracted and then purified by Nickel column. This purified 
protein would be used to study the interactions between Vimentin and Z-ajoene by 
proteomics, western blot and in vitro binding assays. 
 
Results and Discussion 
2.1.1 Vimentin gene was isolated from cDNA. 
The two most important factors during primer design were to achieve a good 
complementarity sequence with the Vimentin coding sequence as well as finding 
matching melting temperatures (i.e. annealing temperatures) for both primers. 
The Forward and Reverse primers were designed with the help of the Vimentin 
coding sequence taken from NCBI and was found to be NM_003380.3. The coding 
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sequence (see Figure 7) was then used to design the forward and reverse primers, 
which would allow a Vimentin PCR product of 1.4 kb to be isolated, with the help 
of the program DNA Man. 
Figure 7: The coding sequence of human Vimentin gene (highlighted in gray) from NCBI 
website. 
 
The primer sequences were the following: 5'-GGA TCC CAT GTC CAC CAG 
GTC CGT GTC-3' and 5'-GTC GAC TTC AAG GTC ATC GTG ATG 
CTG-3' for forward and reverse primers respectively, and both had a length of 27 
base pairs (bp). Their melting temperatures were 65.7 °C for the forward primer and 
61.2 °C for the reverse primer, which were somewhat high but still good 
considering that the difference between them was not more than 5°C (SA 
biosciences). Before the start of the PCR reaction, both forward and reverse primers 
were each diluted to 10 μM (see materials and methods section).  
Moreover, the forward primer sequence contained the Bam HI enzyme restriction 
(RE) site (in red), while the reverse primer contained the Sal I RE site (in blue). 
These two sites were very important because the Vimentin fragment was localized 
between these RE sites when cloned into the Topo vector.  
Briefly, master mix for two PCR tubes was made by adding 10 µM of each primer, 
nucleotides, Taq polymerase, buffer with magnesium (Mg) and nuclease free water; 
so that each PCR tube could hold a total volume of 50 μL. Then, the Vimentin 
cDNA was added to one PCR tube; while the negative control was prepared without 
cDNA to verify the absence of contaminants which could be present in the reaction 
mixture. All tubes were left in the thermal cycler machine for about two hours to 
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allow the reactions to take place. The thermal cycler machine was set for the first 
time to 30 cycles and then increased to 40 cycles to obtain a more abundant PCR 
product and according to the Promega protocol for Taq® PCR Systems core. Then 
the PCR tubes were taken out and were stored at 4°C. 
The PCR product was mixed with blue loading dye to allow the tracking of the 
DNA during  gel electrophoresis. This was carried out according to standard 
procedures with 1% agarose gel after PCR, in order to see if the Vimentin gene had 
been successfully amplified from the cDNA. The Gene Ruler 1 kb DNA ladder was 
used as a marker as an indication of band size. The Vimentin cDNA reaction and 
the negative control were loaded, and electrophoresis was run. When  completed, 
the gel was exposed to UV–light and the DNA bands detected due to the presence 
of ethidium bromide, which binds to DNA and emits fluorescence. In the 
visualization of the gel by the trans-illuminator, we detected only one band in the 
sample with the cDNA (see Figure 8). Moreover, this band was 1.4 kb in size, 
meaning  that the Vimentin gene had been isolated successfully. 
 
Figure 8: Vimentin PCR product. 
Results from the gel electrophoresis with only one band showing the successfully amplified 
Vimentin gene of size 1.4 kb. 
 
With the successful isolation of Vimentin, the PCR product was purified according 
to the Promega protocol (Wizard® SV Gel and PCR Clean-up System kit), in order 
to exclusively leave the pure Vimentin gene and remove all the PCR reaction 
components, as Taq polymerase. Before storing at -20 ° C, the purified PCR 
product was labeled Vimentin, and the DNA content was quantified by the 
Nanodrop spectrophotometer (see Table 1). A good result was obtained, in fact, the 
absorbance ratio at 260 and 280 nm should be between 1.8 and 2, indicating that the 
Vimentin purification has been successful. 
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Table 1: Quantification of the purified Vimentin gene by the Nanodrop spectrophotometer. 
 
 
2.1.2 Vimentin was inserted into the Topo vector and transformed into BL 21 
star DE3 competent cells. 
In order to later be able to clone the purified Vimentin gene into the pET-22b (+) 
expression vector its sequence had to be ligated into the Topo cloning vector 
(TOPO® TA Cloning Kit for Sequencing, Invitrogen).  
The Topo vector is a plasmid linearized to roughly 4 kb in size, to which has been 
covalently bound a topoisomerase (enzyme responsible for the supercoiling of 
DNA), which is characterized by the presence of single 3' thymidine (T) overhangs, 
which allows for the insertion of PCR to ligate efficiently with the vector. 
Furthermore, the vector also contains the genes for resistance to antibiotics 
Ampicillin (Amp) and Kanamycin, which makes it insensitive to action of these 
drugs.  
 
Because the concentration of our purified Vimentin is not very high, we decided to 
use the maximum concentration to be sure to insert Vimentin in Topo vector 
according to the Life technologies protocol for TOPO® TA Cloning Kit for 
Sequencing. Briefly, we mixed purified Vimentin with salt solution and Topo 
vector. The reaction was incubated at room temperature for 30 minutes and then 
stored at -20 °C until we were ready to proceed with the butanol purification to 
remove all components of the reaction through a precipitation. Therefore butanol 
was added to the Topo vector reaction, and after centrifugation the supernatant was 
removed and the pellet resuspended in nuclease free water.  
 
Finally, the transformation into competent cells was performed by adding the 
purified Topo vector to a vial of TOP10 cells. Using the heat-shock, the entrance of 
the plasmid was carried out. Later, the TOP10 cells were incubated for one hour 
with S.O.C. medium (a nutrient-rich bacterial growth medium) to stimulate 
bacterial growth, and a small amount of this was spread in a selective Luria –
Bertani (LB) agar –plate, containing Amp, and incubated overnight. The negative 
control was performed to verify that there were no other bacterial contaminations. 
 
The following day, we found that only two colonies had grown in the Topo sample, 
named Vim–Topo 1 and Vim–Topo 2 clones respectively, and nothing in the 
negative control. In fact only the bacteria, where the Topo vector was present, 
acquired resistance to this antibiotic, as they were able to grow on the  Amp–LB 
agar –plate. 
 
 Conc.(ng/ μl) 260/280 
Vimentin 36.5 1.91 
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2.1.3 Colony screening and isolation of each Vim–Topo clone 
A small amount of each colony was taken with a tip, and first, it was added to a new 
PCR tube for carrying out colony PCR screening; and then added in a falcon tube 
with LB medium broth, which contained Amp, to allow only the growth of the 
selected clone. 
The colony PCR screening is a technique that is used to identify the clones which 
have the gene of interest cloned in the Topo vector, in our case the Vimentin gene. 
Briefly, the PCR reaction was carried out in the presence of the primers for 
Vimentin, Taq polymerase, nucleotides, and buffer. The PCR reaction was run for 
40 cycles under the same conditions as described in the materials and methods 
section. The products of this reaction were separated by agarose–gel 
electrophoresis and assessed on the trans–illuminator. 
The colony screening showed that only in the Vim –Topo 1 clone band was present 
whereas the Vim–Topo 2 clone was absent (Figure 9). Moreover, the Vim–Topo 1 
clone band was a 1.4 kb in size, which suggested that the Vimentin gene was 
inserted correctly. 
 
Figure 9: Colony screening of Vim-Topo clones. 
Visualization by gel electrophoresis of both Vim–Topo clones following the PCR reaction.  
 
For the growth of the selected clone, as described above, each Vim-Topo clone was 
grown in the presence of LB broth medium which contains Amp for one night. The 
LB medium is a clear broth, but could become more turbid depending on the 
bacterial charge (amount of bacteria grown in it). 
In contrast with the colony screening, both selective cultures showed abundant 
bacterial growth, indicating the presence of the vector in both clones. Considering 
these conflicting data and the possibility of drawing erroneous conclusions, we 
decided to analyze both clones. 
Thus, DNA from each culture was purified according to the protocol of the Wizard 
plus SV minipreps DNA purification system kit and the DNA was resuspended in 
nuclease free water and quantified by the Nanodrop spectrophotometer (see Table 
2). 
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 Conc. (ng/µl) 260/280 
Vim –Topo 1 43,5 1,86 
Vim –Topo 2 60,4 1,85 
 
Table 2: Quantification of purified DNA of each Vim–Topo clone by the Nanodrop 
spectrophotometer. 
 
A good result was obtained from both clones where an absorbance ratio at 260 and 
280 nm was found to be  1.8, indicating that the purification has been successful. 
Moreover, in both clones we had good DNA content, especially for the Vim-Topo 2 
clone. 
Considering these conflicting data, we drew two hypotheses. The first hypothesis 
would be that there was a mistake in the preparation of colony screening, where 
probably an insufficient amount of bacteria was added and then the PCR reaction 
did not take place. 
Another hypothesis could be that the bacteria of the Vim-Topo 2 clone was 
transformed by the empty Topo vector. With these results we were not able to rule 
out either of the two hypotheses, so we had decided to use both clones for the 
following investigations. 
 
2.1.4 Sequencing of Vimentin from both Topo clones. 
Before the RE digestion, both Vim–Topo clones were sent off to Central DNA 
Sequencing Facility laboratory of University of Stellenbosch for sequencing 
electrophoresis analysis. This technique allows verification that the sequence 
obtained agrees with the Vimentin gene sequence from the NCBI website, which 
was later confirmed. 
 
The sequencing was divided in three different phases: a PCR reaction, a separation 
by capillary electrophoresis and finally an optical detection (see material and 
methods section). 
The sequencing was performed with the Topo primers. An additional verification 
step was performed for the other two primers named sequence 1 and 2 respectively. 
The primer sequence 1 was the following: 5'-ACC AAC GAC AAA GCC CGC 
GT-3', and the primer sequence 2 was 5'-TCC CTC ACC TGT GAA GTG GA-3' 
respectively, and both had a length of 20 base pairs (bp). Their melting 
temperatures were 55.8 °C for the sequence 1 primer and 53.7 °C for the sequence 2 
primer, were good because they were not high and the difference between them was 
not more than 5°C (SA biosciences). 
 
The Vimentin gene sequencing of the Vim–Topo 1 clone, detected with the M13 
reverse primer (see Topo vector map in materials and methods section), is shown in 
figure 10 and 11.  
 
 
With this primer, we were not able to verify the sequence of the entire Vimentin 
gene but only the initial portion.  
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Figure10: The raw DNA sequence in Vim-Topo 1 clone obtained with M13 reverse primer. 
Using the M13 reverse primer, DNA sequencing of the Vim-Topo 1 clone showed this 
sequence. 
a) The correct sequence of Vimentin is highlighted in gray and bold, in yellow is 
highlighted the ATG start codon, while green is the region recognized by the primer 
sequence 1. In red is indicated unrecognized nucleotides by the software, and these 
have been corrected manually through use of the chromatogram.  
b) It is shown a representative portion of the chromatogram obtained with the M13 
reverse primer. 
 
 
Furthermore, as shown by the figure 10, the software was not able to correctly 
recognize all nucleotides, especially where an overlap of signals of different 
nucleotides occurred. So, it was necessary to check the chromatogram manually 
and then the sequence was corrected through use of the chromatogram (figure 11). 
 
 
 
 
 
 
 
(a) 
(b) 
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Figure 11: The sequencing of Vimentin gene in Vim-Topo 1 clone obtained with M13 reverse 
primer after checking of the chromatogram. In red, the nucleotides were manually 
corrected based on the color display of the individual peaks in the chromatogram. 
 
 
 
Despite the manual correction of the sequence detected with the M13 reverse 
primer, the Vimentin sequence, inserted in Vim–Topo 1 clone,  appeared with 
different mutations and in particular in the region recognized by the sequence 1 
primer (figure 11). Furthermore the inability to verify this sequence in other 
chromatograms, allowed us to conclude that the Vim–Topo 1 clone had inserted the 
Vimentin fragment but its sequence was incorrect probably due to erroneous 
amplification during the PCR reaction. 
 
Therefore, we started to analyze the sequencing data of the Vim–Topo 2 clone. The 
sequencing obtained with the M13 reverse primer produced a long gene sequence 
shown in figure 12, and the quality of this sequencing was high, in fact only two 
bases were not recognized by the software and the manual adjustment has been 
performed (figure 12 –c) following the display of the chromatogram. 
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(a) 
(b) 
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Figure 12: Sequencing of the Vimentin gene in the Vim-Topo 2 clone obtained with M13 
reverse primer. 
Using the M13 reverse primer, DNA sequencing of the Vim-Topo 2 clone showed this 
sequence. 
a) The correct sequence of Vimentin is highlighted in gray and bold, in yellow is 
highlighted the ATG start codon, while green is the region recognized by the 
primer sequence 1. In red is indicated unrecognized nucleotides, and these have 
been corrected manually through use of the chromatogram.  
b) A representative portion of the chromatogram obtained with the M13 reverse 
primer. 
c) In red, the nucleotides were manually corrected based on the color display of the 
individual peaks in the chromatogram. 
 
Considering the good sequencing of the Vim–Topo 2 clone with the M13 reverse 
primer, we proceeded with the analysis of the fragment obtained with sequence 1 
primer. 
 
The sequencing with sequence 1 primer was obtained with  excellent quality. The 
long portion of the Vimentin gene was  correct even after the recognition site of 
sequence 2. The manual correction was carried out on only a few bases located 
within the correct Vimentin sequence (figure 13). 
(c) 
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Figure 13: The sequencing of Vimentin gene in Vim-Topo 2 clone obtained with sequence 1 
primer. 
Using the sequence 1 primer, DNA sequencing of the Vim-Topo 2 clone showed this 
sequence. 
(a) 
(b) 
(c) 
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a) The correct sequence of the Vimentin gene is highlighted in gray and bold, while 
blue is the region recognized by the primer sequence 2. In red is indicated 
unrecognized nucleotides, and these have been corrected manually through use of 
the chromatogram.  
b) A representative portion of the chromatogram is obtained with the sequence 1 
primer. 
c) In red, the nucleotides were manually corrected based on the color display of the 
individual peaks in the chromatogram. 
 
Considering these promising data, we finally analyzed the sequencing of the 
terminal portion of the Vimentin gene obtained starting from the sequence 2 primer. 
This sequencing was excellent because it was not necessary to manually make any 
correction (figure 14). 
 
 
 
Figure 14: The sequencing of Vimentin gene in Vim-Topo 2 clone obtained with sequence 2 
primer.  
Using the sequence 2 primer, DNA sequencing of the Vim-Topo 2 clone showed this 
sequence. 
a) The correct sequence of the Vimentin gene is highlighted in gray and bold.  
b) A representative portion of the chromatogram is obtained with the sequence 2 primer. 
(a) 
(b) 
58 
 
 
Contrary to Vim-Topo 1 clone, the sequencing data revealed that the Vimentin 
sequence of the Vim-Topo 2 clone was  correct. Therefore we cconcluded that the 
insertion of Vimentin gene in Topo vector had taken place successfully in the 
Vim-Topo 2 clone, that it was therefore selected for the following assays.  
 
2.1.5 Restriction enzyme site digestion analysis 
Waiting for the results of sequencing, a RE site digestion analysis was performed in 
both Vim-Topo clones. Thus, the purified DNA of each selective culture was  
subjected to digestion with appropriate restriction enzymes (RE). The REs are 
enzymes produced by bacterial cells, which may be considered as molecular 
"clippers", because they allow the cutting of double strand DNA in fragments. The 
cut takes place in correspondence with short specific base sequences (4-8 bases), at  
restriction sites.  
During the previous amplification of the Vimentin gene, the used primers contained 
one recognition site for the Bam HI and Sal I REs respectively, and the Vimentin 
fragment has been inserted between these two sites. 
To liberate only the Vimentin gene from the Topo vector, a double digestion with 
Sal I and Bam HI enzymes was performed.  
Thus, we prepared a reaction mixture with both Bam HI and Sal I enzymes, and the 
purified DNA from each clone was added. The reaction was then incubated at 37° C 
and a double digestion was made. The products of double digestion were separated 
by agarose –gel electrophoresis and assessed on the trans–illuminator. 
As shown in figure 15, we found that two bands were present as a result of double 
digestion with Bam HI and Sal I enzymes in both the Vim–Topo clones. The larger 
band was detected at 4 kb being the DNA of Topo vector. The smallest band of size 
1.4 kb, is the same size of Vimentin gene. Therefore, we assume that  the double 
digestion had liberated the Vimentin gene from the Topo vector successfully in 
both Vim-Topo clones. 
 
 
Figure 15: Double digestion with Sal I and Bam HI enzymes of Vim-Topo vector clones. 
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Gel electrophoresis of Vim-Topo clones following the double digestion with Bam HI 
and Sal I.  
 
After the sequencing data had shown that the Vim-Topo 2 clone had successfully 
inserted the correct Vimentin sequence,  a new double digestion was performed by 
increasing the concentration of the sample. Electrophoresis gel was run and the 
band corresponding to the 1.4 kb band was cut out and purified according to the 
Promega protocol of Wizard® SV Gel and PCR Clean-up System kit. The DNA 
names Vimentin 2, was resuspended, and quantified using the NanoDrop 
spectrophotometer (see Table 3). 
 
 Conc. (ng/µl) 260/280 
Vimentin 2 15,4 2,02 
 
Table 3: Quantification of the purified Vimentin 2 obtained following  double digestion with Bam 
HI and Sal I restriction enzymes, using the Nanodrop spectrophotometer. 
 
We found that the concentration of Vimentin 2 was not particularly high, with the 
260/280 ratio being at the maximum limit. This DNA content reduction was caused 
by the various steps that were necessary to purify the Vimentin gene. 
This phase is particularly important because purified Vimentin gene can be thus 
inserted into a new cloning/expression vector, said pET22b+ vector, which it is able 
to synthesize the Vimentin protein. 
 
2.1.6 Preparation of the pET22b+ cloning / expression vector 
The pET System is one of the best systems so far developed for the cloning and 
expression of recombinant proteins, such as Vimentin, in the E.coli strain BL 21 
star DE3. 
 
We had chosen the pET-22b(+) cloning/expression vector as it is a stable vector, 
making it good for cloning and expression purposes of the Vimentin protein, 
moreover the presence of a His Tag, means it is possible to purify the Vimentin 
protein expressed by the vector via a Nickel column. This vector also had the Ap 
gene, which is responsible for resistance to Amp antibiotic. Finally, all target genes 
were cloned into pET plasmids under control of strong bacteriophage T7 
transcription; and the expression was induced by providing a source of T7 RNA 
polymerase in the host cell. 
 
Before insertion of the Vimentin gene, the pET-22b(+) vector must be prepared to 
accept it. Firstly, the stock of the pET-22b(+) vector (Novagen) was diluted 1:10 
and 1:100 in nuclease-free water to ensure isolation of colonies. Each dilution of 
pET-22b(+) vector was transformed into BL 21 star DE3 competent cells by 
heat-shock, and then incubated with S.O.C. medium to stimulate bacterial growth. 
A small amount of this bacterial suspension was spread in a selective Luria–Bertani 
(LB) agar–plate, containing Amp, and incubated overnight. The negative control 
was performed to verify that there was no other bacterial contamination. 
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The following day, we found that the negative control had not grown, confirming 
the absence of contaminants; instead, in both pET–plates there were numerous 
colonies present, showing that the transformation had occurred successfully with 
both dilutions.  
 
Three colonies of the 1: 100 pET–plate were therefore identified and selected. A 
small number were  taken with a tip, then tempered and incubated overnight in LB 
medium broth, which contains Amp, to allow only the growth of the selected clone. 
The LB medium is a clear broth, but could become more turbid depending on the 
bacterial charge. 
All selective cultures showed abundant bacterial growth, indicating the presence of 
the vector in all the clones and thus we proceeded with the DNA purification of 
each culture according to the protocol of the Wizard plus SV minipreps DNA 
purification system kit. The DNA was then resuspended and quantified by the 
Nanodrop spectrophotometer (see Table 4 below). 
 
We found that the DNA concentrations of pET–1, –2 and –3 clones were 33.9, 22 
and 34 ng/µl, respectively. These DNA concentrations were not very however 
purification of clones 1 and 2 was successful, in fact, the absorbance values of 
260/280 ratio were around 1.8. Instead, the purification of pET–3 was not 
successful as indicated by the absorbance value of 260/280 ratio that was over 2.  
 
 
 Conc. (ng/µl) 260/280 
pET– 1 33,9 1,87 
pET– 2 22 1,89 
pET– 3 34 2,17 
 
Table 4: Quantification of the purified DNA of each pET –clone by the Nanodrop 
spectrophotometer. 
 
Since the concentration of pET–1 clone was higher than the of pET–2 clone, we  
decided to only use this clone for subsequent assays. 
 
Analyzing the map of the pET-22b(+) vector, we identified each restriction site for 
the Bam HI and Sal I enzymes respectively, which were the same REs used in the 
previous cloning in Topo vector. 
Thus, we prepared a reaction mixture using both Bam HI and Sal I enzymes, Bam 
HI buffer and the purified DNA of each clone was added. Digestion was carried out 
and then gel electrophoresis was run and assessed on the trans–illuminator. 
As shown in figure 16, in the gel was present only one well-defined band at 5.5 kb 
in size, confirming that the double digestion was carried out successfully. 
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Figure 16: Double digestion of pET 1 clone by Bam HI and Sal I REs . 
Gel electrophoresis of pET-1 clone following the double digestion with Bam HI and 
Sal I.  
 
Given that the enzymes had acted correctly, a new double digestion was performed 
by increasing the concentration of the sample. The electrophoresis gel was run and 
the 5.5 kb band (pET vector size) was cut out and purified according to the Promega 
protocol of Wizard® SV Gel and PCR Clean-up System kit. The DNA was 
resuspended, named B/S–pET–1, and finally quantified using the NanoDrop 
spectrophotometer (see Table 5). 
 
 Conc. (ng/µl) 260/280 
B/S-pET-1 21,6 2,01 
 
Table 5: Quantification of the purified DNA of pET –1 clone after double digestion with Bam HI 
and Sal I REs using the Nanodrop spectrophotometer. 
 
We found that the concentration of pET-1 was 21.6 ng/µl, which is not particularly 
high, and the 260/280 ratio is the maximum limit for considering its purification as 
positive. 
Thus, we proceeded with the removal of phosphate groups from the 5'- and 3'-ends 
of the pET vector DNA to prevent its self–ligation before the insertion of the 
Vimentin fragment. Briefly, purified DNA of B/S–pET–1 clone was mixed with 
Shrimp alkaline phosphate enzyme and its specific buffer, then incubated at 37° C 
to allow removal of phosphate groups. After one hour, the enzyme was inactivated 
by incubating at 65° C and the reaction was then purified according to the Promega 
protocol of Wizard® SV Gel and PCR Clean-up System kit. The DNA was 
resuspended, named SAP–pET–1, and finally quantified using the NanoDrop 
spectrophotometer (see Table 6). 
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 Conc. (ng/µl) 260/280 
SAP-pET-1 16,7 2,03 
 
Table 6: DNA quantification of SAP-pET –1 clone after phosphate elimination using the Nanodrop 
spectrophotometer. 
We found that the concentration of SAP–pET–1 was quite low amounting to 16.7 
ng/µl, and the 260/280 ratio is the maximum limit for considering its purification as 
positive. This reduction of DNA content was caused by the various steps that were 
necessary to the preparation of pET vector prior to allowing insertion of the 
Vimentin fragment. 
 
2.1.7 Ligation of Vimentin gene in pET22b+ vector and Transformation in BL 
21 star DE3 competent cells 
After the SAP –pET–1 vector and Vimentin 2 insert were prepared for ligation, and 
their concentrations were determined, we prepared a reaction mixture in which the 
molar ratio of vector / insert was a 1/3. In this reaction, we added the T4 ligase 
enzyme and its respective buffer. The negative control was prepared without the 
Vimentin 2 insert. Both samples were incubated overnight at 16° C to allow for 
ligation between the pET vector and Vimentin. 
Before the transformation into competent cells, both ligation samples were purified 
by butanol precipitation, in order to remove all of the reaction components. Once 
the supernatant was removed and the DNA was resuspended in nuclease –free 
water. 
 
Finally, the transformation into competent cells was performed by adding in each 
vial of BL 21 star DE3 cells the purified ligation reaction or the negative control. 
Using the heat-shock, the entrance of the plasmid was carried out. Later, the BL 21 
star DE3 cells were incubated for one hour with S.O.C. medium to stimulate 
bacterial growth, and a small amount of this was spread in a selective LB agar–
plate, containing Amp, and incubated overnight.  
The following day, we found that uncountable colonies had grown in the ligation 
sample, and nothing in the negative control. These data had shown that the ligation 
process was successful. Thus, in the ligation plate, eight well–isolated colonies 
were selected for subsequent analysis and named Vim-pET clones. 
 
 
2.1.8 Colony screening and isolation of each Vim –pET clone 
The procedure is the same for the Vim–Topo vector clones (see above). Thus for 
colony PCR screening and culture isolations, eight Vim –pET clones were selected. 
The PCR reaction was run and its products were separated by agarose–gel 
electrophoresis and assessed on the trans–illuminator. 
The colony PCR screening showed that a band at 1.4 kb (Vimentin size) was 
present in all the clones indicating that the ligation was successful (figure 17). 
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Figure 17: Colony screening of Vim-pET clones. 
Visualization of the gel electrophoresis of both Vim–pET clones following the PCR 
reaction.  
 
For the growth of the selected clone, as described above, each Vim-pET clone was 
grown overnight in Amp –LB broth medium. The following day, all selective 
cultures showed an abundant bacterial growth, indicating the presence of the vector 
in all the clones. 
Thus, the DNA of each culture was purified according to the protocol of the Wizard 
plus SV minipreps DNA purification system kit and its DNA was resuspended in 
nuclease free water and quantified by the Nanodrop spectrophotometer (see Table 
7). 
 
 
 Conc. (ng/µl) 260/280 
Vim –pET 1 62,3 1,56 
Vim –pET 2 63,2 1,60 
Vim –pET 3 53,6 1,54 
Vim –pET 4 46,9 1,60 
Vim –pET 5 50,1 1,64 
Vim –pET 6 61,6 1,62 
Vim –pET 7 50,5 1,64 
Vim –pET 8 49,2 1,54 
 
Table 7: Quantification of the purified DNA of each Vim –pET clone by the Nanodrop 
spectrophotometer. 
 
A good result was obtained from purification of the isolated culture although the 
absorbance ratio at 260 and 280 nm was slightly below the value of 1.8, indicating 
that the purification was not perfect but still good. Moreover, in all the Vim-pET 
clones we had a good DNA content, and it was very similar in all the samples. 
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2.1.9 Restriction enzyme site digestion analysis 
To liberate only the Vimentin gene from the pET vector, a double digestion with 
Sal I and Bam HI enzymes was performed. Thus, we prepared a reaction mixture 
with both Bam HI and Sal I enzymes, and the purified DNA from each clone was 
added. The reaction was then incubated at 37° C and  double digestion was made. 
The products of double digestion were separated by agarose–gel electrophoresis 
and assessed on the trans–illuminator. 
As shown in figure 18, we found that two bands were present as a result of double 
digestion with Bam HI and Sal I enzymes in all Vim–pET clones, except for the 
Vim-pET-4 clone. The larger band was detected at 5.5 kb, in the DNA of pET 
vector. The smallest band was a size of 1.4 kb, which was the Vimentin fragment. 
 
Figure 18: Double digestion of Vim-pET clones by Bam HI and Sal I.  
Gel electrophoresis of Vim –pET clones following the double digestion with Bam HI 
and Sal I.  
 
It appears that the double digestion had liberated the Vimentin gene from the pET 
vector successfully in all Vim –pET clones, except to Vim –pET-4 clone. 
 
2.1.10 Sequencing of Vimentin from two pET clones 
Except for the Vim –pET-4 clone, all the other clones had inserted the Vimentin 
fragment in the pET vector. Moreover, considering the data of DNA quantification 
from isolated culture, the first two clones had the highest concentration (i.e. Vim –
pET-1 and Vim –pET-2 clones) so they were selected for sequencing at the Central 
DNA Sequencing Facility in the laboratory of University of Stellenbosch.  
The procedure was the same as used for the Topo vector (see above), but this 
sequencing was performed with the pET-22b(+) primers, being T7 promoter and T7 
terminator. 
 
Analyzing the sequencing data of Vim–pET-1 clone, we found that the Vimentin 
sequence had inserted in this clone with many mutations, probably due to erroneous 
amplification during the PCR reaction. The inability to verify this sequence in other 
chromatograms, allowed us to conclude that the Vimentin sequence of Vim –pET-1 
clone was incorrect and it was deleted. 
 
The Vim–pET-2 clone data are shown below. We found that the T7 promoter was 
not able to sequence the entire Vimentin fragment, but only its initial portion. 
Furthermore, the sequencing quality provided by the software was high, and with 
only a few bases to check again manually. After these corrections, the Vimentin 
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sequence was correct for an extended part after the recognition site of the sequence 
1 primer (figure 19). 
 
 
 
 
 
 
 
Figure 19: The sequencing of Vimentin gene in Vim- pET 2 clone obtained with T7 Promoter. 
(b) 
(c) 
(a) 
66 
 
 
Using the T7 promoter primer, DNA sequencing of the Vim-pET 2 clone was shown. 
a) The correct sequence of Vimentin is highlighted in gray and bold, in yellow is highlighted 
the ATG start codon, while green is the region recognized by the primer sequence 1. In 
red is indicated unrecognized nucleotides, and these have been corrected manually 
through use of the chromatogram.  
b) A representative portion of the chromatogram obtained with the T7 promoter primer. 
c) In red, the nucleotides were manually corrected based on the color display of the 
individual peaks in the chromatogram. 
 
Considering that the correct sequence of Vimentin in the Vim –pET-2 clone 
obtained with the T7 promoter, we proceeded with the data analysis of the 
sequencing with sequence 1 primer. 
 
Also, the sequencing with sequence 1 primer was obtained with excellent quality. 
The long portion of the Vimentin gene was perfectly correct even after the 
recognition site of sequence 2. The manual correction was carried out on only a few 
bases located within the correct Vimentin sequence (figure 20). 
 
 
 
 
 
(a) 
(b) 
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Figure 20: Sequencing of the Vimentin gene in the Vim–pET 2 clone obtained with sequence 1 
primer. 
Using the sequence 1 primer, DNA sequencing of the Vim- pET 2 clone was shown. 
a) The correct sequence of Vimentin gene is highlighted in gray and bold, while blue is 
the region recognized by the primer sequence 2. In red is indicated unrecognized 
nucleotides correctly by the software, and these have been corrected manually 
through use of the chromatogram.  
b) A representative portion of the chromatogram obtained with the sequence 1 primer. 
c) In red, the nucleotides were manually corrected based on the color display of the 
individual peaks in the chromatogram. 
 
Considering these promising data, we finally analyzed the sequencing of the 
terminal portion of the Vimentin gene obtained starting from the sequence of primer 
2 (figure 21). In this case, the provided data by the software had been very good, 
and a manual corrections were made on only a few bases (figure 21-c). 
 
 
(a) 
(c) 
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Figure 21: Sequencing of the Vimentin gene in the Vim–pET 2 clone obtained with 
sequence 2 primer.  
Using the sequence 2 primer, DNA sequencing of the Vim-pET 2 clone is shown. 
a) The correct sequence of Vimentin gene is highlighted in gray and bold.  
b) A representative portion of the chromatogram obtained with the sequence 2 primer. 
c) In red, the nucleotides are manually corrected based on the color display of the 
individual peaks in the chromatogram. 
 
Contrary to Vim–pET-1 clone, analyzing all the sequencing data of Vim –pET-2 
clone we found that the sequence of Vimentin was inserted successfully. 
Confirming that all the cloning process were carried out correctly, after the end of 
the Vimentin sequence was present at the recognition site for Sal I RE.  
Moreover, after analysis (see figure 21), we found that about twenty bases from the 
Sal I RE site, were also present in a region coding for a tail of poly-histidine 
(poly-His) immediately followed by a stop codon. This poly-His tail is essential 
during the step of protein purification.  
Thus, the purified Vimentin protein could be used to evaluate the effect of Z-ajoene 
on this protein by in vitro assays, such as proteomics, western blot and in vitro 
binding assays. Unfortunately due to technical problems in the purification lab, it 
was not possible to purify the Vimentin protein from the Vim–pET 2 clone. 
However, this phase of the process will be performed in the future (Manuscript in 
preaparation).  
(b) 
(c) 
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2.2 Z-ajoene influences the intracellular organization of Vimentin 
protein on MDA-MB-231 cancer cells 
 
The background of this section is based on our previous work where we found that 
ajoene S-thiolates numerous protein targets in MDA-MB-231 cells [C. H. 
Kaschula, et al. (2015) Mol Carcinog.]. By 2D electrophoresis the ajoene-targeted 
and labelled proteins were separated and one of these proteins was identified by 
proteomics to be Vimentin. 
 
In this section, we aimed to confirm Vimentin is indeed a target of the garlic 
compound ajoene. We therefore aimed to confirm S-thiolation of Vimentin by 
ajoene and to identify whether the ajoene-Vimentin interaction is important in the 
anti –cancer activity of ajoene in the triple-negative breast cancer cell line 
MDA-MB-231. 
 
 
Results and Discussion 
 
2.2.1 Dansyl-Ajoene (DP) and Z-Ajoene (ZA) S-Thiolate Vimentin at 
Cys328 
 
As described in our article we found that the ajoene S-thiolates numerous proteins 
in MDA-MB-231 cells through mixed disulfide formation between ajoene and a 
cysteine residue of a protein [C. H. Kaschula, et al. (2015) Mol Carcinog.]. 
Subsequent to the paper, we found that one of these labeled proteins was separated 
from the MDA-MB-231 cell lysate by 2D-gel electrophoresis and identified by 
proteomics to be Vimentin. 
As mentioned above the first step of the project was therefore to clone and express 
recombinant Vimentin, useful to validate that Vimentin is an S-thiolation target of 
ajoene. We performed this assay using a synthetic ajoene analogue called DP, in 
which one of the allyl groups is substituted for a dansyl group. This ajoene analogue 
was found to be fully active compared to ajoene at inhibiting proliferation and 
inducing apoptosis in MDA-MB-231 cells.  
The dansyl group of DP was chosen as in addition to being fluorescent which makes 
it useful for fluorescence studies, there is also a commercially available anti-dansyl 
antibody against it which allows its detection for immunoblotting investigations. 
As described in our previous article, we had demonstrated that DP and ajoene share 
the same targets, and thus DP can be a useful tool for understanding the mechanistic 
aspects of ajoene.  
Since we were unsuccessful in expressing and purifying recombinant Vimentin, we 
purchased some protein from a company to use for in vitro experiments, i.e. 
proteomics and alkylation assay.  
We therefore treated purified recombinant Vimentin (1 µM) with 25 µM DP in the 
absence of reducing agents. We observed the formation of a covalent bond only in 
the treated sample by western blot which was evidenced by the transfer of the 
dansyl label from ajoene to Vimentin during thiolysis. Furthermore, by subjecting 
all the samples to the reducing agent DTT, the DP label was cleaved off the protein 
(Figure 22) thereby confirming that DP binds Vimentin via a disulfide linkage. 
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Figure 22: Dansyl –ajoene S-thiolates recombinant Vimentin protein   
Scheme depicting proposed mechanism of Vimentin S-thiolation involving transfer of the 
dansyl group from DP to Vimentin.  
(i) Western blot showing dansylated Vimentin in DP-treated samples when run under 
non-reducing conditions only. Purified Vimentin (1 µM) samples were either untreated or 
treated with 25 µM DP. Same samples treated without (non-reducing) or with (reducing) 
100 mM dithiothreitol (DTT). 
 
We were therefore confident that Vimentin is indeed one of the ajoene targets in 
MDA-MB-231 cells and that it is targeting Vimentin through S-thiolation of a 
cysteine residue. When considering the Vimentin amino acid sequence, it is 
immediately evident that there is only a single cysteine amino acid in the Vimentin 
sequence at position 328 (see Fig 23 below). It is therefore highly possible that Cys 
328 is the target site of ajoene in Vimentin.  
 
Figure 23: Amino acid sequence of Human Vimentin.  
In bold is highlighted the fragment of interest, which is one of those generated by trypsin 
digest (see the text below). This fragment contains the Cysteine 328 (in red), which  is the 
amino acid which is proposed to be involved in S-thiolation with ajoene. 
(i) 
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We therefore prepared three Vimentin samples by incubating purified recombinant 
Vimentin protein without (control) or with 100 µM (a) ZA or (b) DP and sent these 
samples for proteomics analysis at the Centre for proteomics and Genomics 
research (CPGR), Cape Town, South Africa. 
The proteomic analysis is a sensitive analytical technique which allows 
identification of protein peptides by mass analysed  by mass spectrometry. This 
technique therefore can give information about whether the protein has been 
covalently modified [J. Rappsilber et al. (2003) Anal. Chem]. Briefly, the pure 
protein is first subjected to enzymatic digestion by the trypsin. This protease 
cleaves the protein at the level of the C-terminal after either lysine or arginine [J. V. 
Olsen et al., (2004) Mol. Cell. Proteomics]. Therefore a protein fragment mixture is 
formed, and the peptides are then separated by liquid chromatography coupled to 
mass spectrometry analysis that enables fragment identification against a known 
data base of the expected fragments for that protein (See figure 24 below). If the 
fragment is not detected than it may be modified and therefore a different mass to 
that of the native protein in the database. 
 
Figure 24: Proteomic analysis of a protein 
The experimental procedure of proteomic analysis of a protein. First, the protein is 
subjected to proteolytic digestion by trypsin to generate peptide fragments. These 
fragments are then separated by liquid chromatography that it is coupled to mass 
spectrometry analysis which enables a identification of the protein based on expected mass 
of fragments within a known database for the protein.  
 
According to Expasy peptide software, the predicted mass to charge ratio (m/z) of 
the Vimentin fragment QVQSLTCEVDALK could be a number of options 
depending on the charge of the peptids (Figure 25 (i)): 
[M] = 1432.7232 
[M+H]+ = 1433.7304 
[M+2H]2+ = 717.3688. 
By experimental analysis we found the mass of the untreated fragment to be 
717.3689, meaning that the peptide was identified and that the parent ion carries a 
2+ charge ([M + 2H]2+) (Figure 25(ii)). 
The fragment masses of the treated samples were found to be different in the 
Z-ajoene and DP-treated samples being 72.00337 and 322.08096 respectively.  
So, if we apply this formula: 
 
Modified fragment: (Compound MW + Fragment MW+ 2xHydrogens). 
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The predicted mass of the modified fragment by Z-ajoene is (72.00337 +1432.7233 
+ 2x1.0078)/2 = 753.3711, whereas for DP–fragment is (322.08096 + 1432.7233 + 
2x1.0078)/2 = 878.4099 (Figure 25 (i)): 
By proteomic analysis, we found that the fragment masses of ZA-treated and 
DP-treated samples are 753.3708 and 878.4096, respectively (Figure 5(ii)).  
These masses are identical to the predicted masses (Figure 5(iii)). These data are a 
very excellent result, because this confirms our hypothesis that both Z-ajoene and 
its analogue DP covalently modify Vimentin through S-thiolation at Cysteine 328 
of Vimentin (Figure 5(iii)). These data have validated and confirmed our finding 
that DP S-thiolates a Vimentin target protein in MDA-MB-231 breast cancer cells. 
Vimentin is therefore an intracellular drug target of ajoene in MDA-MB-231 cells. 
 
 
Figure 25: Z-Ajoene and DP S –thiolates Vimentin through Cysteine 328. 
(i) Using Expasy peptide software we predicted the masses of the Vimentin fragment in 
untreated, ZA and DP –treated samples. 
(ii) Proteomics showing S-thiolated Vimentin in all samples treated with ajoenes. Vimentin 
samples (10 µg) untreated and treated with DP or ZA (both 100 µM) were sent to CPGR 
Laboratory for peptide analysis. In accordance with the differences of their mass, the 
chromatograms had showed different retention times for the three samples. 
(iii) Table showing predicted vs experimental masses, confirming that both DP and ZA that 
bind covalently to Cysteine 328. 
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2.2.2 Ajoene disrupts the structure of Vimentin filaments in MDA-MB-231 
breast cancer cells. 
 
We next sought to establish whether covalent modification of the Vimentin protein 
at Cys-328 with ajoene may cause a structural modification to the protein. 
Thus, to evaluate the potential effects of ajoene on the Vimentin structure, the triple 
negative breast cancer cell line, MDA-MB-231, was treated with Z-ajoene and the 
fluorescent ajoene analogue DP, and fluorescence was detected by 
immunofluorescence using antibodies for Vimentin.  
 
When selecting the correct concentration of Z-ajoene and DP for this experiment, 
we aimed to find a non-cytotoxic concentration in which the cellular integrity was 
not compromised. We therefore first performed an MTT cell viability assay prior to 
performing immunofluorescence staining of the Vimentin protein in 
MDA-MB-231 cells. We found that 25 µM of Z-Ajoene or DP is not cytotoxic to 
MDA-MB-231 cells after 6 hours of treatment, as shown in Figure 26, where the 
values of cell viability of the treated samples are not different to those of the 
untreated control. Cell viability was measured by the MTT cell viability assay. 
Figure 26: Cytotoxicity of 25 µM DP or 25 µM Z-Ajoene in MDA-MB-231 breast cancer cells 
by the MTT assay. 
Using an MTT cell viability assay, 25 µM DP or Z-Ajoene was found not to be cytotoxic to 
MDA-MB-231 breast cancer cells after six hours of treatment. 
 
Vimentin forms structural filaments mainly in the cytoplasm but there is also a 
small amount anchored within the membranes as well as in the ER and in the 
mitochondria [Katsumoto T. et al. (1990). Biol Cell]. 
The intracellular organization of Vimentin can be evaluated by 
immunofluorescence assays, where the Vimentin is detected through the use of 
specific antibodies against it. We have two commercially available vimentin 
antibodies in our laboratory being a polyclonal antibody H84 and a monoclonal 
antibody V9.  
The H84 antibody is a rabbit polyclonal IgG subclass, that can recognize multiple 
epitopes corresponding to amino acids 1–84 mapping at the N–terminus of 
Vimentin protein which is a region of Vimentin embedded in the membrane 
[Georgatos S. D., et al. (1985) Journal of Cell Biology] and is therefore better used 
for detection of membrane Vimentin.  
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The V9 antibody is a mouse monoclonal IgG1 subtype that recognizes the epitope 
corresponding to the C-terminal domain of Vimentin protein, and is therefore 
sensitive to the detection of cytoplasmic Vimentin. The stains therefore resemble 
more filaments which are located in the cytoplasm.  
 
For Vimentin immunofluorescence, MDA-MB-231 cells were seeded on a glass 
cover-slip and treated with 25 µM DP or Z-ajoene in 0.1% DMSO for six hours. 
Control cells were treated with 0.1% DMSO alone. Thereafter, the cells were fixed 
and stained with one of the primary Vimentin antibodies (V9 or H84) followed by 
treatment with a secondary antibody coupled to a red fluorescent Cy3 fluorophore. 
Cell sections were mounted on a glass slide for viewing under the confocal 
microscope.  
 
DP emits blue/green due to the presence of its fluorescent dansyl–group; whereas 
the Vimentin protein emits red due to the Cy3 fluorescent secondary antibody. The 
treated samples are displayed in separate channels (Blue/Green and Red) and in an 
overlaying channel to verify any possible co–localization of DP and Vimentin. We 
have previously found that ajoene localizes to the ER in MDA-MB-231 cells. The 
vast majority of Vimentin in the cell is cytoplasmic with some membrane and its 
small amount is located into the ER. 
 
In untreated cells, detection by a the primary polyclonal Vimentin antibody (H84) 
revealed the filamentous structures of Vimentin which is probably cytoplasmic and 
membranous comprising long and branched filaments of the cytoskeleton. The 
Vimentin is also localized in the plasma membrane(see Fig 27-B below), but it not 
detected when Vimentin is localized in ER, probably the epitope is different and 
H84 antibody cannot recognized it. 
Figure 27: The intracellular organization of Vimentin detected by the H84 polyclonal antibody. 
In order to view the intracellular organization of Vimentin, Vimentin in MDA-MB-231 was 
detected with a H84 anti-vimentin antibody and stained with a red with Cy3. In (B), 
Vimentin protein was found to form long and branched cytoplasmic filaments, and it is also 
localized in plasma membrane. (A)The phase contrast image is shown.  
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In DP- and Z-ajoene- treated cells, we observed that the intracellular organization of 
Vimentin was not so well defined and that the signal was less intense. Vimentin was 
found to be mainly localized in the plasma membrane with the structures appearing 
more dispersed, with significant reduction in integrity of the filamentous structures 
(Fig 28-A and C). Moreover, in DP-treated cells, H84 –antibody detection did not 
revealed co–localization between DP and Vimentin (Fig. 28- C) although this was 
not unexpected as we had previously determined that DP localizes to the ER and a 
vast majority of Vimentin is in the cytoplasm. 
Figure 28: Effect of DP and Z-Ajoene on Vimentin protein detected by H84 primary polyclonal 
vimentin antibody in MDA-MB-231 breast cancer cells. 
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To determine whether Vimentin and Ajoene co-localize in cancer cells, MDA-MB-231 
cells were treated with the fluorescent ajoene analogue (DP). Vimentin filaments were 
detected with the H84 anti–vimentin antibody and stained red with Cy3. The image of DP–
treated cells shows that Vimentin (red channel, A) and DP (blue channel, B) didn’t 
co-localize (both red and blue channels, C) . The image of ZA –treated cells shows that the 
Vimentin filament is located mainly at the plasma membrane and dispersed in cytoplasm 
(in red, E). (D) The phase contrast to ZA-treated cells is shown. Moreover, both DP and 
Z-ajoene caused structural changes in the Vimentin filaments (C and E). 
 
To confirm these data, we also analyzed the Vimentin intracellular organization 
using a primary monoclonal Vimentin antibody V9. 
In the untreated control, V9–appeared to detect Vimentin localized to the nuclear 
membrane but mostly the Intermediate Filaments of cytoskeleton (Fig 29-B). 
Furthermore, it would seem that the Vimentin localized in the ER is not detected 
even by V9 antibody, probably the epitope is different and not recognized by this 
antibody; or the ER –bound Vimentin signal is so weak that it is hidden by their 
abundant cytoplasmic filaments. What we know is that we have failed to see clearly 
Vimentin localized in the ER. 
 
Figure 29: The intracellular organization of Vimentin detected by the V9 monoclonal 
antibody. 
To display intracellular organization of Vimentin, untreated MDA-MB-231 cells were 
subjected to immunofluorescence, where the Vimentin filaments were labelled with the V9 
anti–vimentin antibody and labelled red with Cy3. (B) Vimentin appeared filamentous and 
localized in long and branched cytoplasmic filaments and in the nuclear membrane . (A) 
The phase contrast image is shown. 
 
In both DP- and ZA-treated samples, we observed that the intensity of the Vimentin 
fluorescent signal was reduced, the structures appeared more dispersed, and there 
was a significant reduction in integrity of the filamentous structures in the 
cytoplasm (Fig 30-C and -E).  
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Figure 30: Effect of Ajoene on Vimentin protein detected by V9 primary monoclonal in 
MDA-MB-231 breast cancer cells. 
To determine whether Vimentin and Ajoene co-localize in cancer cells, MDA-MB-231 
cells were treated with the fluorescent ajoene analogue (DP), and blue fluorescence was 
detected using immunofluorescence, instead Z-ajoene (D and E) does not emit 
fluorescence. All samples are also treated with primary vimentin antibody (V9, 
monoclonal) and the Cy-3 fluorescently-tagged secondary antibody that emitted red 
fluorescence. The image of DP –treated cells shows that Vimentin (in red, A) and DP (in 
blue, B) didn’t co-localize (both red and blue channels, C). The image of ZA –treated 
cells shows that a intracellular organization of Vimentin (in red, E) was changed  and 
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mainly located at the plasma membrane. (D) The phase contrast to ZA-treated cells is 
shown. Moreover, both DP and Z-ajoene caused structural changes in the Vimentin 
filaments (C and E).  
 
In accordance with disruption of Vimentin structures, we also observed a change in 
cell morphology where the cells assumed a more rounded shape compared to the 
physiological dendritic shape, in the presence of ajoene (Figure 31). 
Figure 31: Change in morphology induced by Ajoene in MDA-MB-231 cells. 
By the confocal microscope, the cell morphology was observed in untreated (A) and 
ajoene-treated (B) MDA-MB-231 cells. As shown here, the MDA-MB-231 cells 
physiologically had a dendritic morphology (A), when these cells were treated with 25 
µm ajoene assumed a rounded shape (B). 
 
In fact, Vimentin plays a major role in the maintenance of strong and stable cell 
morphology by participating in the formation of intermediate filaments [A. Satelli 
& S. Li, (2011) Cell Mol Life Sci.], consequently we propose that the disruption of 
the Vimentin filaments may lead to an alteration of the cytoskeleton and a change in 
cell morphology. 
 
It is not too surprising that there is not co–localization between DP and Vimentin as 
we had previously found that DP localizes to the ER and Vimentin is broadly 
expressed in the cytoplasm where it is a structural protein of intermediate filaments, 
however it is also found embedded in all membranes and anchored in mitochondria 
and ER [Katsumoto T. et al (1990) Biol Cell]. 
There is only probably a small amount of DP interacting with Vim compared to the 
overwhelming localization of DP in the ER where it S-thiolates the vast majority of 
its protein targets. It is probably only a small amount of ER –anchored Vimentin 
which is interacting with DP and Z-ajoene and this is sufficient to cause the 
structural changes that we observe.  
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Conclusions 
We have found that Z-ajoene and its analogue DP interact with Vimentin in 
MDA-MB-231 breast cancer cells. In fact, in MDA-MB-231 cell lysates treated 
with ajoene were extracted and the dansyl –labeled Vimentin protein was detected.  
Given that the vast majority of DP or Z-ajoene accumulates in the ER, a site where 
only a small amount of ER –bound Vimentin is present, it is not surprising that 
drug/protein co-localization experiments gave negative results. However, as it has 
been indicated by in vitro experiments (i.e. proteomics and alkylation assays), 
Z-ajoene/Vimentin interactions do readily occur via a direct binding of Z-ajoene 
with the cysteine 328 of Vimentin. Thus, although only a small amount of the 
cellular Vimentin is involved in the reaction, it seems sufficient to cause the 
disruption of Vimentin filaments leading to an alteration of the cytoskeleton and a 
change in the cell morphology in MDA-MB-231 breast cancer cells. 
In conclusion, these data sustain that the cytoskeleton protein Vimentin is 
unquestionably one of Ajoene targets and indicate that its binding to the protein 
may play a role in the anti-cancer activity of Z-ajoene in MDA-MB-231 human 
triple-negative breast cancer cells. (Manuscript in preparation) 
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Chapter III –Studies on the anti-metastatic  
activity of Z-ajoene 
 
Introduction 
 
Metastasis is the most common cause of death among women with breast cancer. 
Triple-negative breast cancers (TNBC) comprise approximately 15 % of breast 
cancers [De Santis C. et al., (2011) Curr. Oncol.].  
 
TNBC is characterized by the absence of the estrogen receptor (ER), progesterone 
receptor (PR) and lack of overexpression of the human epidermal growth factor 
receptor 2 (HER2). This breast cancer subtype is responsible for high mortality due 
to the highly invasiveness and migratory capacity of this cancer. Moreover, there 
are limited clinical targeted therapies to TNBCs and these cancers frequently 
develop chemotherapy resistance. Therefore new and effective chemotherapies are 
needed for this cancer subtype [Wolfe A. R. et al., (2015) Breast Cancer Res Treat]. 
 
The breast metastatic phenotype is characterized by elevated expression of 
mesenchymal markers such as Vimentin and N-cadherin, and decreased expression 
of epithelial markers such as E-Cadherin (figure 32) [Satelli & Li (2011) Cell Mol 
Life Sci; C. Foroni et al. (2012) Cancer Treatment Reviews]. More specifically, it is 
reported that the Vimentin protein is over-expressed in metastatic cancers, 
including that of the breast, and that Vimentin overexpression correlates with an 
invasive phenotype [Satelli & Li (2011) Cell Mol Life Sci]. 
 
This invasive phenotype may in part be directly or indirectly regulated by Vimentin 
through epithelial-mesenchymal transition (EMT) (Figure 32 and 33). EMT is a 
cellular reprogramming process in which epithelial cells acquire both invasive and 
the migratory capacity, that are typical of mesenchymal cells.[Wei J. et al, (2008) 
Anticancer Research]. 
Vimentin may also act by breaching the basement membrane, and by facilitating 
dissociation of cells from the original tumor with the invasion into new tissue (See 
figure 32 and 33). 
 
It is well established that Vimentin knockdown in cancer cell lines inhibits the 
metastatic phenotype [Vuoriluoto K, et al. (2011) Oncogene; D.C.Y. Phua et al. 
(2009) Molecular Biology of the Cell] making Vimentin an attractive therapeutic 
target. Furthermore, studies have shown that transgenic mice lacking functional 
Vimentin develop normally suggesting that Vimentin inhibitors may exhibit limited 
toxicity [Colucci-Guyon et al (1994) Cell].  
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Figure 32: Vimentin's role in the metastatic process. [Satelli & Li (2011) Cell Mol Life Sci] 
 
On a signaling level, Vimentin is proposed to play a role in metastasis though a 
number of pathways. The PI3K/AKT signaling pathway had been shown to be 
up-regulated in many tumors. In this pathway, AKT1 kinase phosphorylates 
Vimentin at serine 39, thereby inhibiting caspase-induced proteolysis of Vimentin 
[M. E. Kidd et al. (2014) American Journal of Respiratory Cell and Molecular 
Biology].  
 
Phosphorylated Vimentin may up-regulate various events involved in EMT. For 
example, phosphorylated Vimentin has been shown to interact with the 14-3-3 
proteins. 14-3-3 proteins are a family of highly conserved proteins which play 
crucial roles in regulating multiple cellular processes, including cell cycle 
regulation, DNA repair, apoptosis, cell adhesion, and motility [Liu T-A et al. (2013) 
PLOS ONE]. The interaction of Vimentin with 14-3-3 proteins serve as a cofactor 
for the inactivation of Raf kinase [G. Tzivion et al. (1998) Nature] thus preventing 
the assembly of the Raf/14-3-3 complex (figure 33, on the left) [G. Tzivion, et al. 
(2000) Journal Biological Chemistry]. This leads to activation of the MEK/ERK 
signaling pathway and the transcription and expression of genes that involve in the 
regulation of EMT process (figure 33, on the left).  
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Figure 33: Role of Vimentin in cell signaling. 
First, AKT1 acts by phosphorylating Vimentin and is thus able to up-regulate several 
signaling pathways. Then, phosphorylated Vimentin can induce AXL expression to 
stimulate cell migration (on the right) or bind to 14-3-3 and to prevent the inactivation of 
Raf kinase and the up-regulation of the MEK / ERK signaling pathways (on the left) 
[Satelli & Li (2011) Cell Mol Life Sci].  
 
Phosphorylated Vimentin may also promote the EMT modification by regulating 
Axl expression. It has been demonstrated that Axl expression correlates with 
motility and invasiveness in breast cancer cells [Zhang YX et al. (2008) Cancer 
research ; X. Wu et al. (2014) Oncotarget].  
 
Axl is a TAM receptor which belongs to the subfamily of receptor tyrosine kinases 
(RTKs) that include Tyro3 and Mer [Y Li et al. (2009) Oncogene]. This receptor is 
composed of two immunoglobin-like domains and dual fibronectin type III repeats 
in the extracellular region and a cytoplasmic kinase domain [Y Li et al. (2009) 
Oncogene].  
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Figure 34: Axl signaling pathways.  
Axl plays important signaling roles in cell proliferation, survival, migration, and 
inflammation This figure is adapted from Wu X. et al. [Wu X. et al. (2014) Oncotarget].  
 
Axl can be activated through a number of different mechanisms, but 
ligand-dependent dimerization (principally driven by Gas-6) is crucial in the 
activation of the PI3K/AKT pathway, which is one of the most important signaling 
pathways involved in the migration of breast cancer (Figure 34) [X. Wu et al. 
(2014) Oncotarget]. In invasive mesenchymal breast cancer cells, Vimentin is 
reported to play a key role by acting as Axl inducer, which then operates through 
Slug- and Ras- pathways to cause an increase in cell motility in breast cancer 
[Vuoriluoto K et al. (2011) Oncogene]. 
Axl activation induces the mesenchymal phenotype by acting simultaneously on 
multiple signaling pathways according to the type of signal received. 
 
Another possible pathway through which Vimentin may facilitate migration is 
through the protein kinase Src. Src is another cellular factor that plays a crucial role 
during tumor development and progression. Src was the first proto-oncogene 
discovered (normal gene that encodes a protein usually involved in regulation of 
cell growth or proliferation and that can be mutated in a oncogene by altering its 
expression) and is a protein kinase involved in numerous cellular signal 
 
Gas-6 
 
P-Vimentin 
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transduction pathways (Figure 35). Overexpression and aberrant activation of Src 
family kinases have been identified in various human tumours, including the breast 
cancer [Irby RB & Yeatman TJ (2000) Oncogene ; Coluccia AM et al. (2006) 
Cancer Res]. 
 
 
 
 
 
Figure 35: Src activation promotes cell migration.  
Src activation plays a central role in activating multiple signaling pathways in the 
induction of metastatic cancer cells [R. B Irby & T. J Yeatman, (2000) Oncogene ] 
 
 
Wei et al have demonstrated that Vimentin and Src kinase are physically linked in 
human prostate cancer cells, and that this interaction influences the E-cadherin / 
β-catenin complex which is involved in the formation of cell-cell adherent 
junctions (Figure 36) [Wei J. et al, (2008) Anticancer Research]. Activated Src acts 
through the phosphorylation of β-catenin at the tyrosine residue 654. This event 
causes a 6 fold reduction in the affinity of β-catenin to E-cadherin [Roura S. et al. 
(1999) J Biol Chem]. The partial or complete dysfunction of the 
E-cadherin/β-catenin complex causes decreased stability of cell-cell adherent 
junctions, the loss of epithelial polarization and the nuclear translocation of 
β-catenin [Thakur R & Mishra DP (2013) J Cell Mol Med]. 
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Figure 36: Schematic representation of the intracellular interactions involved in the formation 
of cell-cell adherent junctions [E. Dejana et al. (2009) Developmental Cell] 
 
 
Upon dissociation of β-catenin from E-cadherin, free β-catenin can act as a key 
signal transducer in the Wnt signaling pathway, which is involved in polarized cell 
migration and cell-cell adhesion [Nelson & Nusse, (2004) Science]. 
 
In the absence of Wnt signaling, cytoplasmic β-catenin is normally recruited by the 
multiprotein complex, which consists of Axin, APC (product of the tumour 
suppressor gene adenomatous polyposis coli) and glycogen synthase kinase-3β 
(GSK-3β). This complex facilitates GSK-3β to induce the hyper-phosphorylation 
of β-catenin which promotes its ubiquitination and subsequent its degradation via 
the ubiquitin-proteasome pathway [JC Howard, et al. (2003) BMC Musculoskeletal 
Disorders]. 
 
However, in the presence of the Wnt signal, GSK-3β activity is inhibited, leading to 
the accumulation of β-catenin in the nucleus where it interacts with the Lef/Tcf 
(lymphoid enhancer factor /T-cell factor) family of transcription factors to activate 
he β-catenin-mediated gene transcription [Nelson & Nusse, (2004) Science; J. Qi, 
et al.; (2006) Molecular Biology of the Cell]. 
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Figure 37: Canonical Wnt/β-catenin pathway.  
β-catenin is a component of cell-cell adherent junctions with E-Cadherin, and a key 
signaling factor in the Wnt pathway. [J. Qi et al. (2006) Molecular Biology of the Cell] 
 
There are literature reports that several organosulfur compounds extracted from 
garlic, are effective at inhibiting metastases. These include Diallyl disulfide 
(DADS) [Xiao et al., (2014) Plos one; Huang et al, (2015) Mol Nutr Food Res], 
S-allylmercaptocysteine (SAMC) [Howard et al, (2007) Clin Cancer Res ] Diallyl 
trisulfide (DATS) and ajoene [J. Huang et al. (2015) Mol. Nutr. Food Res]. 
 
Interestingly, Huang et al. are the first and the only ones reporting that DADS 
causes a dose-dependent decrease in Vimentin protein levels in human 
triple-negative breast cancer [Huang et al, (2015) Mol Nutr Food Res]. 
 
Both DADS [Xiao et al, (2014) Plos one] and DATS [K-C Lai et al. (2015) J. Cell. 
Mol. Med] were found to decrease Src expression in human triple-negative breast 
cancer and in human colon cancer, respectively.  
 
The β -catenin pathway was down –regulated by DADS in a dose– and time–
dependent manner, increasing E–cadherin expression and decreasing levels of free 
β–catenin [Huang et al, (2015) Mol Nutr Food Res]. In agreement with these 
findings, SAMS was found to suppress the metastatic phenotype via the up –
regulation of E–cadherin, increasing the cell-cell adherent junctions [Howard et al, 
(2007) Clin Cancer Res ]. 
 
Ajoene inhibit both primary tumor growth and metastasis of B16/BL6 melanoma 
cells in C57BL/6 mice [Taylor P. et al. (2006) Cancer Letters], but there are no 
studies that identify the signaling pathways involved in this inhibition. 
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Therefore, there are no studies linking the antimetastatic potential of garlic 
compounds to Vimentin, although some of the downstream signaling pathways of 
Vimentin have been identified (i.e. Axl, Src, β-Catenin / E-cadherin complex). 
Thus, seen the involvement of Vimentin in the regulation of these proteins, it is very 
likely that Vimentin has been strongly implicated in metastasis. Since we found that 
ajoene targets Vimentin and causes structural changes to the filaments, we decided 
to test whether ajoene itself can inhibit the migratory capacity in invasive breast 
cancer cells, and which signaling pathways are involved. 
 
 
 Results and Discussion 
3.1 Z-Ajoene inhibits cell migration in the MDA-MB-231 invasive breast 
cancer cell line  
 
Since elevated concentrations of Z-ajoene induce apoptosis in cancer cells, it was 
important for us to find a lower non-cytotoxic concentration for studies on the anti –
metastatic activity of Z-ajoene in MDA-MB-231 cells. In previous experiments, we 
found that at the 6 h timepoint, 25µM Z-ajoene was not cytotoxic to MDA-MB-231 
cells, , but we had the need to treat the cells for 24 h, which represent the timepoint 
for the wound healing assay. We therefore performed an MTT cell viability assay 
prior to testing for anti-metastatic activity by the wound healing assay. We tested 
the cell viability of MDA-MB-231 cells following treatment with three different 
concentrations of Z-ajoene, namely 5, 10 and 20 µM of Z-ajoene for 24 hours. We 
found that Z-ajoene at 5 µM and 10 µM was not cytotoxic to MDA-MB-231 cells 
(Figure 38), in which the percentage of cell viability compared to the negative 
control (untreated with 1% FBS) was found to be 108 and 98 % respectively; while 
20 µM Z-ajoene for 24h displayed a small cytotoxic effect (83 %), although this 
was not significant.  
 
 
Figure 38: Cytotoxicity of Z-Ajoene in MDA-MB-231 breast cancer cells after 24h treatment 
MDA-MB-231 cells were exposed to different concentrations of Z-ajoene (in medium with 1% 
FBS) for 24 h under the same experimental conditions as that of the wound healing assay, and cell 
viability was evaluated by the MTT assay. Control cells received 1% FBS and 0.1 % DMSO alone. 
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Data is presented as a percentage of the mean ± SD of three independent experiments vs. untreated 
control (1% FBS). 
 
We then assessed the effect of Z-ajoene (5, 10 and 20 µM) on cell migration in 
MDA-MB-231 cells (Figure 39). Due to the highly invasive nature of breast 
cancers, we investigated the effect of Z-ajoene on the motility of MDA-MB-231 
cells in vitro using a wound healing assay. 
Briefly, MDA-MB-231 cells were seeded in a six-well plate and allowed to attach 
overnight. The following day a wound was introduced in the presence of different 
concentrations of Z-ajoene (5, 10 and 20 µM) in 1% FBS. We also prepared two 
different untreated controls: one containing only 1% FBS (negative control) to 
detect the physiological wound closure in the absence of chemotactic agents; and 
the other containing 10% FBS (positive control) to stimulate complete closure of 
the wound in the presence of a chemoattractant. It was also important to track the 
same wound region as a function of time. To allow easy detection of these zones, 
lines perpendicular to the wound were marked on the bottom of each well. Each of 
these zones were then photographed at timepoints 0 and 24 h, and free area was 
quantified by ImageJ software at both time points. The area quantification of each 
zone was processed by applying the following formula: 
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where a higher value indicates lower migration ability. 
To greater emphasize the migratory ability, data is also represented in terms of a 
migration distance ratio using the following formula: 
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where a higher value indicates a greater migration ability. 
 
After 24 hours, we found that the wound was completely closed in the positive 
control, while the negative control (no chemotactic agent added) only migrated by 
65 %. Cells treated with Z-ajoene + 1 % FBS showed reduced migration in a 
dose-dependent manner. Z-ajoene (5 µM) treatment caused reduced migration by 
51 % in MDA-MB-231 cells when compared to the complete wound closure 
(positive control) (Figure 39), but we do not believe that this concentration was 
particularly effective, although the data are significant (** p value < 0.01), because 
it was near to the physiological closure of the negative control (65 % respect to the 
complete wound closure). However, 10 µM and 20 µM Z-ajoene caused a greater 
inhibition, in which the wounds only healed 30 % and 22 % respectively, when 
compared to the positive control (Figure 39) and the data are convincingly 
significant (*** p value < 0.001) versus negative control (1% FBS).  
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Figure 39: Dose–dependent effect of Z-Ajoene on migration in the MDA-MB-231 human triple 
negative breast cancer cell line.  
A wound is introduced into a 90% confluent monolayer of MDA-MB-231 cells followed by 
addition of different concentrations of Z-ajoene (5, 10 and 20 µM) in 0.1% DMSO and 1% 
FBS. The negative (1% FBS) and positive (10% FBS) controls were performed. After 24 
hours, the wounded areas is photographed by phase-contrast microscopy using an inverted 
microscope (Olympus CKH41) (ii) in three different regions to assess wound closure and 
quantified by ImageJ software (i). Data represents triplicate determinations of a single 
experiment which was repeated in duplicate. ** p < 0.01 and *** p < 0.001 vs. untreated 
Z-Ajoene (negative control, 1% FBS). 
 
Z-ajoene appears to be inhibiting migration in a dose-dependent manner however 
we preferred to use a concentration of 10 µM Z-ajoene as this was convincingly 
shown to not cause any cytotoxicity.  
We therefore performed a wound healing assay in which the control produced 
marked cell migration, characterized by a physiological closure of 45% compared 
to the 10% FBS sample, in which the wound area was completely closed after 24 h 
(Figure 40). Wounds exposed to 10 µM Z-Ajoene in medium with 1% FBS showed 
significant delays in healing (Figure 40 (ii)). Specifically, as indicated by the 
quantitative analyses (Figure 40 (i)), exposure to 10 µM Z-Ajoene for 24 h inhibits 
cell migration by 67% compared to the untreated control (negative) and the data are 
highly significant (***p < 0.001). 
(ii) 
(i) 
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Figure 40: Effect of Z-Ajoene on migration of human breast cancer cells in the presence of 1 % 
FBS. 
For the wound healing assay, MDA-MB-231 cells were seeded and allowed to attach 
overnight. A vertical wound was created into a 90% confluent monolayer. The cells were 
exposed to 10 µM Z-Ajoene for 24 h with 1% FBS. After 24 hours, the wounded areas 
were recorded by phase-contrast microscopy using an inverted microscope (Olympus 
CKH41) and were photographed (ii) in six different regions to assess wound closure and 
quantified by ImageJ software (i). Quantitative assessment of wound reduction is 
expressed as the percentages of mean ± SD of three independent experiments. ***p < 
0.001 vs. untreated Z-Ajoene (control, 1% FBS). Assays were carried out in triplicate but 
the one displayed above is that of a single experiment (Figure 39). 
 
(i) 
(ii) 
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We then investigated whether 10 µM Z-ajoene caused an inhibitory effect in the 
presence of a chemotactic agent that stimulates both proliferation and migration 
(Figure 41). Thus, MDA-MB-231 cells were treated with 10 µM Z-ajoene in the 
presence of 10% FBS for 24 h. We found that wounds exposed to 10 µM Z-ajoene 
showed reduced healing in breast cancer cells. Quantitative analysis showed that 
Z-Ajoene inhibits cell migration by 40% compared to the untreated control 
(positive) and that the data are highly significant (*** p<0.001). 
Figure 41: Effect of Z-Ajoene on migration of human breast cancer cells in the presence of 
10% FBS. 
The wound healing assay was performed as described before. MDA-MB-231 cells were 
exposed to 10 µM Z-Ajoene for 24 h, but in the presence of the chemoattractant (10 % 
FBS). The wounded areas were quantified by phase-contrast microscopy using an 
inverted microscope (Olympus CKH41) and (ii) were photographed in six different 
regions at designated times to assess wound closure and quantified by ImageJ software 
(i). Quantitative assessment of wound reduction is displayed as the percentages of mean ± 
SD of two independent experiments. ***p < 0.001 vs. untreated Z-Ajoene (positive 
control, 10 % FBS). Assays were carried out in duplicate but the one displayed above is 
that of a single experiment (Fig. 39).  
(i) 
(ii) 
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These results have shown that at non-cytotoxic concentrations, Z-Ajoene 
effectively inhibits the migration of the highly invasive breast cell line 
MDA-MB-231 both in the presence and absence of a chemotactic agents, but the 
best effect induced by 10µM Z-ajoene is the one we observed in the absence of 
chemoattractant agent, where there is an inhibition of the cell migration equal to 
70%.  
Although 10 µM Z-ajoene is not cytotoxic in MDA-MB-231 after 24 hours, we 
found that the Z-ajoene –treated cells were beginning to assume a bit rounded 
morphology. This cell morphological change, as we have demonstrated before, is 
caused by the disruption of the Vimentin filaments and the consequent 
rearrangement of the cytoskeleton. Thus, we supposed that Vimentin protein play a 
key role in the cell migration of MDA-MB-231 breast cancer cells. 
 
3.2 Z-ajoene stimulates Vimentin expression in MDA-MB-231 breast 
cancer cells  
It is reported that Vimentin plays an important role in metastasis, and that its 
overexpression is involved in the increased motility and invasiveness in breast 
cancer. [Korsching E, et al. J Pathol. (2005); A. Satelli & S. Li (2011) Cell Mol Life 
Sci]. 
We have shown that Z-ajoene interacts directly with Vimentin by forming a mixed 
disulfide with Cys328 and that Z-ajoene causes disorganization of the Vimentin 
filaments in MDA-MB-231 breast cancer cells. We therefore hypothesize that 
binding of Z-ajoene to Vimentin may cause a structural change in the protein which 
may affect the ability of these cells to migrate. In order to test this hypothesis, we 
investigated the effect of Z-Ajoene on Vimentin and some of its downstream targets 
involved in metastasis.  
We therefore silenced the expression of Vimentin protein in MDA-MB-231 cells to 
see whether removal of the protein has a similar effect to treating with Z-ajoene. 
MDA-MB-231 cells were therefore plated and allowed to attach overnight. The 
following day, cells were transiently transfected with two different concentrations 
(50 or 100 nM) of Vimentin SiRNA. After 6 h, media containing the transfection 
mixture was replaced with fresh culture media and the cells were incubated for 24, 
48 or 72 h. Cells were then lysed and the lysate subjected to Western blot analysis. 
 
Figure 42: Silencing of Vimentin in MDA-MB-231 cells.  
Cells were incubated for 6 hours with 50 or 100 nM SiRNA diluted in Lipofectamine® 
RNAi MAX Reagent. Thereafter, the media was replaced and the cells were incubated for 
24, 48 and 72h. Cells were then lysed and subjected to Western blot analysis using the 
antibodies indicated. β-Tubulin was used as an internal loading control. The data are 
presented as the fold change compared to the untreated group. 
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As shown in Figure 42, the Vimentin expression is inhibited after 24 hours of 
treatment at both the 50 and 100 nM concentrations of  SiRNA with little 
inhibition exhibited at 72 hours. Maximal inhibition was obtained  at 48 h using 
100 nM SiRNA and therefore these conditions were selected for future experiments 
involving Vimentin knockdown.  
 
Next, we investigated the effect of Z-ajoene on Vimentin expression in the 
triple-negative breast cancer cell line MDA-MB-231. Briefly, MDA-MB-231 cells 
were seeded and allowed to attach overnight. The following day, cells were 
incubated with 10 µM Z-ajoene for time points up to 24 h. After treatment, cells 
were lysed and subjected to Western blot analysis for detection of the Vimentin 
protein.  
We found that Z-ajoene induced an up-regulation of Vimentin in a time-dependent 
manner. In fact, Vimentin expression was found to increase in Z-Ajoene-treated 
cells between 6 and 24 h with the maximal effect at 24 h, in which  the levels were 
found to increase three fold relative to the untreated control (Figure 43).  
 
Figure 43: Effect of Z-Ajoene on Vimentin expression on MDA-MB-231 cells. 
MDA-MB-231 cells were incubated with 10 µM Z-Ajoene up to 24 h. After treatment, 
cells were lysed and subjected to Western blot analysis using the antibodies indicated. 
Silenced Vimentin (SiVim; 100 nM SiRNA after 48h) was used as a knock-down 
Vimentin. β-Tubulin was used as an internal loading control. The blots shown are 
representative of two independent experiments. The data are presented as the fold change 
compared to the untreated group. 
 
We previously found that ajoene compounds affect the ability of the Vimentin 
protein to perform its proper function. It may be possible therefore that the cell may 
compensate for this deficiency by synthesizing more protein.  
 
 
3.3 Z-ajoene reduces the expression of Axl in MDA-MB-231 cells 
It is well established that Axl expression is correlated with the motility and 
invasiveness of breast cancer cells [X. Wu et al. (2014) Oncotarget.; Zhang YX et 
al. (2008) Cancer research]. In a study by K. Vuoriluoto et al, it was found that the 
Vimentin plays a key role in cell migration induced by AXL, acting as its enhancer. 
[Vuoriluoto K et al. (2011) Oncogene.; V. A. Korshunov (2012) Clin Sci; A. Satelli 
& S. Li (2011) Cell Mol Life Sci]. 
We hypothesize that Z-ajoene may covalently bind to Vimentin and therefore affect 
its ability to properly function in the metastasis process which may be through Axl.  
 
We decided to use a concentration of 10 µM Z-Ajoene which we had previously 
shown to be non-toxic to MDA-MB-231 cells up to 24 h. 
We found by Western blot analysis that in the MDA-MB-231 cell line, Axl 
expression was downregulated by 10 µM Z-ajoene at 10 and 24 h by 2 and 4 fold 
respectively (Figure 44), and this result was observed in duplicate experiments . 
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Figure 44: Effect of Z-ajoene on Axl expression in MDA-MB-231 cells.  
MDA-MB-231 cells were incubated with 10 µM Z-ajoene for time points up to 24 h. 
After treatment, cells were lysed and subjected to Western blot analysis using the 
antibodies indicated. SiVim (100 nM SiRNA after 48h) was used as a knock-down the 
Vimentin protein. β-Tubulin was used as an internal loading control. The blots shown are 
representative of two independent experiments. The data are presented as the fold change 
compared to the untreated group. 
 
It is reported that Axl is activated by phosphatidylinositol 3-kinase [Hafizi S. & 
Dahlbäck B. (2006) FEBS Journal], and that Vimentin participates in this process 
by upregulating Axl [Korshunov V. A. (2012) Clin Sci]. Contrary to the report by 
Vuoriluoto et al [Oncogene 2011], we found that the Vimentin depletion did not 
significantly affect the expression of Axl in Vimentin-silenced MDA-MB-231 cells 
(Figure 44). Vuoriluoto et al used the same cell line and found that Axl expression 
was inhibited by 56 % in MDA-MB-231 cells lacking the Vimentin protein. 
However in our study at 48h post transfection we did not see any change in the Axl 
levels although it was not specified in the article the timepoint the authors used. We 
did not look at other timepoints to rule out the lack of an effect in our experiment.  
Importantly we found that Z-ajoene reduces the expression of Axl. This link 
between a garlic compound and Axl expression has not been observed before and is 
a novel result which may play an important role in metastasis inhibition in breast 
cancer cells. But the mechanism by which ajoene induces down–expression of Axl 
is not yet clear and will be the subject of future investigations, we supposed that the 
down-expression of Axl may affect the PI3K pathway, wich is involve in the EMT 
process. 
 
3.4 Z-ajoene reduces the expression of Src in MDA-MB-231 cells 
Src is a signal–transducing protein kinase that plays an important role in the control 
of cell growth and differentiation. The alteration of expression and aberrant 
activation of kinases such as Src is involved in tumor progression [Irby RB & 
Yeatman TJ (2000) Oncogene; Coluccia AM. et al. (2006) Cancer Res; Wei et al; 
(2008) Anticancer Research] 
Damiano et al. reported that Src regulates the motility in breast and colon cancer 
cells by affecting the Ras/ERK signaling pathway [Damiano L et al. (2010) 
Oncogene]. In another paper, Wei et al demonstrated that Vimentin stimulates 
tumor cell invasiveness by regulating the E-cadherin/β-catenin complex via Src in 
prostate cancer cells [Wei et al; (2008) Anticancer Research]. There therefore 
appears to be a link between Vimentin and Src in the progression of metastasis. We 
performed Western blot analyses to determine whether a non-cytotoxic 
concentration of Z-ajoene (10 µM) affects the expression of Src in MDA-MB-231 
cells. This analysis revealed that in the MDA-MB-231 cell line, Z-ajoene induced 
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down-regulation of Src protein in a time –dependent manner. In fact, cells treated 
with Z-ajoene showed a reduction in Src expression from 6 - 24 h with the maximal 
effect at 24 h (Figure 45).  
 
 
Figure 45: Effect of Z-ajoene on Src expression in MDA-MB-231 cells. 
MDA-MB-231 cells were incubated with 10 µM Z-ajoene for various time points up to 24 
h. After treatment, cells were lysed and subjected to Western blot analysis using the 
antibodies indicated. SiVim (100 nM SiRNA after 48 h) was used as a knock-down the 
Vimentin protein. β-Tubulin was used as an internal loading control. The blots shown are 
representative of two independent experiments. The data are presented as the fold change 
versus the ZA untreated group. 
 
Interestingly, and contrary to literature reports [Wei et al (2008) Anticancer 
Research], we found that silencing of Vimentin protein did not affect the expression 
of Src in MDA-MB-231 breast cancer cells. Instead, Wei et al. found that the 
silencing of Vimentin protein caused a reduction of Src expression in the 
antisense-Vimentin transfected prostate cancer cells 1E8-H. The origin of these 
conflicting data could be caused by the diversity of cell lines, in our case of a breast 
cancer cell line while they were using prostate cancer cells. Moreover, the silencing 
procedure was also different, because while they used an antisense–
oligonucleotides transfection, in our experiment we used SiRNA transfection in the 
MDA-MB-231 breast cancer cell line which did not show any reduction in Src 
expression following 48h.  
We did find however that Z-ajoene, like other garlic compounds (DADS & DATS), 
reduces the expression of Src, which may play a role in its anti-metastatic activity in 
MDA-MB-231 breast cancer cells. As mentioned before, Src acts by activating 
β-catenin and PI3K pathways. Thus, down-expression of Src probably inhibits both 
β-catenin and PI3K pathways, blocking the Epitelial-Mesenchymal transition 
process signals and at last the metastasis in MDA-MB-231 breast cancer cells. 
 
 
3.5 Z-Ajoene may influence the β-Catenin / E-Cadherin pathway in 
MDA-MB-231 cells. 
Alteration of the β-catenin signaling pathway is involved in the development and 
progression of various cancers including that of the breast [Huang. et al. (2015) 
Mol. Nutr. Food]. Huang et al reported that DADS inhibits activation of the 
β-catenin pathway, in both MDA-MB-231 and BT-549 cell lines, in both a dose- 
and time-dependent manner [Huang. et al. (2015) Mol. Nutr. Food]. 
Thus, we analyzed lysates of MDA-MB-231 cells by western blot to evaluate 
whether Z-ajoene affects the β-catenin/ E-Cadherin complex.  
As shown in the figure 46, Z-Ajoene was not found to significantly influence the 
levels of β-Catenin/E-Cadherin complex during the first 10 hours of treatment, the 
initial phase of the metastatic process. Between 10 – 24 h a small reduction in 
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phospho-β-catenin expression was found with expression levels around 30-40% of 
the control. Contrary to the literature [Wei et al. (2008) Anticancer Research], in the 
Vimentin knock-down sample, levels of phospho-β-Catenin similar to untreated 
control were observed. 
 
Figure 46: Effect of Z-ajoene on the β-Catenin/E-Cadherin signaling pathway.  
MDA-MB-231 cells were incubated with Z-ajoene for time points up to 24 h. After 
treatment, cells were lysed and subjected to Western blot analysis using the antibodies 
indicated. β-Tubulin was used as an internal loading control. SiVim (100 nM SiRNA after 
48 h) was used as to knock-down the Vimentin protein. The blots shown are 
representative of two independent experiments. The data are presented as the fold change 
versus untreated group. 
 
Wei et al used 1E8-H prostate cancer cells, whose Vimentin was silenced by 
antisense –oligonucleotides transfection. Similar to our results for the Src protein, it 
may be a combination of both the cell line and the silencing procedure which could 
give rise to the conflicting results. However in our experiment, the total lack of 
Vimentin, obtained after 48 h the SiRNA transfection, did not affect the 
phospho-β-catenin levels.  
We did find however that Z-ajoene, like garlic DADS compound, modestly affected 
the phospho-β-catenin levels which may play a role in its anti-metastatic activity, 
probably blocking the Wnt pathway involves in the polarized cell migration in 
MDA-MB-231 breast cancer cells.  
 
 
Conclusions 
The inhibition of cell migration in vitro stands as indication of anti-metastatic effect 
in vivo. At non-cytotoxic concentrations (10 µM), in triple-negative MDA-MB-231 
breast cancer cells, Z-ajoene was able to exert a strong inhibition of the cell 
migration, both in the absence (70% inhibition) and in the presence of a 
chemotactic agent (40% inhibition). So far, our investigations on the molecular 
mechanism(s) of this promising effect of Z-ajoene, showed that the compound 
markedly affect the expression levels of Axl and Src proteins (i.e. 75% reduction), 
and less the phosphorylation of the β–catenin protein (i.e. 40% reduction), 
suggesting that Z-ajoene may affect the regulation of several signaling pathways 
that are known to imply a key role for Vimentin. Interestingly, Z-ajoene caused a 
three-fold increase in the expression of Vimentin in MDA cells. This apparently 
contradictory result may be explained by Z-ajoene inhibition of the Vimentin 
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function in the filament-assembly process, which in turn may up-regulate its 
expression. 
Although other authors in knockout-vimentin cells showed that Vimentin 
determines a down-regulation of Axl, Src and the β-catenin/E-cadherin complex, in 
MDA-MB-231 breast cancer cells we did not confirm these changes. Besides of the 
different cell lines used, reasons of this discrepancy may be also explained by the 
different methods of transfection used.  
Whether the in vitro effect of Z-ajoene on the expression of Axl, Src and the 
β-catenin/E-cadherin complex is mediated by Vimentin or not, our findings 
represent the first report on the activity of Ajoenes on the expression of a protein, 
Axl, responsible for activation of the PI3K pathway implied in the 
epithelial-mesenchymal transition process. 
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Materials and methods (alphabetical order) 
 
Alkylation assay 
Purified recombinant Vimentin protein (1 µM, Prepotech, USA) treated with or 
without Dansyl-Z-ajoene (25 µM) for 2 minutes at room temperature. All samples 
boiled at 95 °C for 5 minutes with or without reducing agent (100 mM dithiothreitol). 
The reaction was detected by immunoblot using anti-vimentin (H84, 1:1000, Santa 
Cruz, Whitehead Scientific, South Africa) anti-dansyl (1:7500, Molecular Probes, Life 
Technologies, South Africa) antibodies, standard protocols were applied.  
 
 
Cell culture 
The MDA-MB-231 cells were purchased from ATCC. Cells were incubated at 37°C 
under 5% CO2 and cultured with antibiotics in D-MEM (Dulbecco’s Modified Eagle 
Medium) containing 10% FBS (Foetal Bovine Serum, Gibco, Life Technologies, 
South Africa). 
 
Cell viability assay 
Cytotoxicity of compounds was evaluated using the standard 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, 
South Africa) cellular viability assay. Briefly, MDA-MB-231 cells at a density of 1.2 
or 3.0 x 105 cells per well were seeded in 6-well plates for immunohistochemistry or 
wound healing assay respectively. Following overnight adhesion, for 
immunohistochemistry cells were incubated with media alone or media supplemented 
with 25µM Z-ajoene or Dansyl-ajoene in DMSO (0.1% v/v, Sigma) at 37◦C for 6 h. On 
the other hand, for wound healing assay, cells were treated with 10 µM Z-ajoene in 
DMSO (0.1% v/v, Sigma) at 37◦C for 24 h. Thereafter, 200 µL/well of 5 mg/mL MTT 
was added and incubated with the cells for 4 h, followed by addition of 2 mL/well 10% 
SLS, 0.01M HCl (Merck, Darmstadt, Germany) to solubilize the formazan crystals. 
The plates were read at 595nm using a Multiscan FC plate reader (Thermo Fischer 
Scientific, Life Technologies, South Africa). The cytotoxicity observed in ZA-treated 
cells was expressed as a percentage of the absorbance measured respect to untreated 
cells. 
 
 
Cloning 
All the cloning steps were included in a logical order. 
1. PCR  
In order to design the primers for the PCR, the access number of Vimentin in 
Homo Sapiens was looked up on the NCBI website and was found to be 
NM_003380.3. The coding sequence was then used to design the forward and 
reverse primers, which would have to allow a Vimentin PCR product of 1.4 kb to 
be isolated, with the help of the program DNA Man.  
There are some important points to take into account during the primer design, 
such as the melting temperature for both primers and the complementarity with 
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the DNA template. It is important that the melting temperature of primers (the 
temperature at which a primer would anneal to the complementary cDNA 
sequence) did not differ by more than 5° C. The PCR should also be set to the 
lowest annealing temperature. Otherwise, if it is set to a temperature higher than 
that, the primer with the lower melting temperature would be no longer able to 
bind to its complementary cDNA sequence, instead of the primer with the higher 
melting temperature, as would in any case in able to bind to a lower temperature. 
 
The sequence of forward primer was 5'-GGA TCC CAT GTC CAC CAG GTC 
CGT GTC-3', and that of reverse primer was 5'-GTC GAC TTC AAG GTC ATC 
GTG ATG CTG-3'. Both the forward and reverse primers were diluted at the 
concentration of 10 μM before the start of the PCR reaction. However, some 
calculations had to be carried out first in order to be able to do so, 
 
M: 
Conc. n
MW
 
 
MW: 330 g mol-1 nt-1 x NT 
Conc.n : 37 μg ml-1 x OD 
 
Where MW, Conc.n and M where given on each bottle of the forward or reverse 
primer. 
 
For the forward primer: (14-2471 code) 
NT: 27 
OD: 550.6 
Molarity: /0 1 2345.4 1 6478 39 23:;<=734
>? 1 @A
 = 
BBC.D 1 EF 1 GCCC
F 1 EEC
 = 2286.44 µM 
In order to obtain the final concentration of the forward primer equal to 10 µM, 
the initial concentration of the forward primer (2286.44 μM) was diluted 1:228. 
So, 1 μl of this stock was added to 227 μl of nuclease –free water.  
 
For the reverse primer (14-2471 code): 
NT: 27 
OD: 745.1 
Molarity: /0 1 2345.4 1 6478 39 23:;<=734
>? 1 @A
 = 
FHB.G 1 EF 1 GCCC
F 1 EEC
 = 3094.13 µM 
In order to obtain the final concentration of the reverse primer equal to 10 µM, the 
initial concentration of the forward primer (3094.13 μM) was diluted 1:309. So, 1 
μl of this stock was added to 308 μl of nuclease –free water.  
 
Thereafter, PCR was done in order to isolate the gene of interest, i.e. the coding 
sequence for Vimentin from the cDNA, and two reactions were carried out 
following the Life technologies protocol for TOPO® TA Cloning Kit for 
Sequencing. Each PCR tube contained the mixture shown in Table 8 and a total 
volume should be of 50 μl. One of these reactions contained the Vimentin cDNA, 
while the other one was used as a negative control and contained nuclease –free 
water.  
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Concentration of stocks Negative control (µL) Vimentin cDNA (µL) 
10ng/µl Vimentin cDNA - 1 
10 nM dNTPs 1 1 
10 µM F primer 1 1 
10 µM R primer 1 1 
Taq Pol 1 1 
10 x taq pol buffer 5 5 
Nuclease-free water 41 40 
Total volume 50 50 
 
Table 8: Components of the PCR reactions, where the cDNA would be substituted by nuclease 
free water for the negative control. 
 
The Taq polymerase is a thermostable DNA polymerase which binds to the 3' end 
of each primer, in order to build a new DNA strand from the cDNA template by 
addition of dNTPs. During the course of the PCR this new DNA strand, i.e. the 
Vimentin cDNA, would get amplified.  
The PCR mixtures were left in the thermocycler machine for about two hours to 
allow the reaction to take place. The thermal cycler machine was set initially to 30 
cycles and then increased to 40 cycles to obtain a more abundant PCR product and 
according to the Life technologies protocol for TOPO® TA Cloning Kit for 
Sequencing:  
 
Initial temperature for denaturation of the DNA: 94° C for 5 minutes 
Temperature for denaturation of the DNA: 94° C for 1 minutes 
Temperature for the annealing of the primers: 50° C for 1 minute       for each cycle 
Temperature for the elongation of the primers: 72° C for 2 minutes 
Final temperature for the complete elongation of the primers: 72° C for 7 minutes 
 
Then the PCR tubes were taken out and their products were mixed together with 
10 μl of blue loading dye (Fermentas), which would allow the tracking of the 
DNA during the subsequent agarose –gel electrophoresis. All the samples were 
finally stored at 4°C until required. 
 
2. Gel electrophoresis 
The gel electrophoresis was carried out according to standard procedures with 1% 
agarose gel after the PCR, in order to see if the Vimentin gene had been 
successfully amplified from the cDNA. 
To start with, 1 grams of agarose were weighted and added into a beaker with 100 
ml of 1x TAE buffer. The beaker with its contents was heated up in the microwave 
oven until the agarose was dissolved and the solution looked transparent. It was 
important to avoid the contents from boiling in the microwave oven, as some 
water could then evaporate and the concentration of agarose would then become 
more than 1%. 
The solution was allowed to cool down, then 10 μl of a 10mg/ml ethidium 
bromide solution was added to it under the fume hood, as ethidium bromide is 
carcinogenic. Ethidium bromide was added as it is a fluorescent dye that 
intercalates with the DNA. When the gel was exposed to UV-light, the ethidium 
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bromide emitted fluorescence and the DNA could be detected. The gel was 
afterwards poured onto a gel chamber and was then left for about 20 minutes to 
solidify. 
Once the gel was solid, the Gene Ruler 1 kb DNA ladder (Fermentas) was used 
and loaded onto the first lane. Then 10 μl of the negative control with blue loading 
dye (Fermentas) was loaded onto the second lane, followed by the Vimentin 
cDNA sample, which contained also the blue loading dye.  
 
 
Figure 47: Gene Ruler 1 kb DNA ladder.  
The size of each band was shown. 
 
To verify that the PCR reaction was successful, gel electrophoresis was performed 
with a small amount of each sample. For this, 10 μl of Vimentin cDNA sample were 
loaded in the gel. The gel electrophoresis was run for about one hour at 60 Volt, 
then the gel was assessed on the trans –illuminator and finally photographed. 
 
If the PCR reaction was successful, a new gel electrophoresis was performed by 
loading the remaining sample to isolate the PCR product, and the gel portion 
corresponding to it was cut out. This fragment was then subjected to purification by 
the Wizard® SV Gel and PCR Clean-Up System kit (see the section below). 
 
3. Purification of PCR products 
Once the gel electrophoresis had been carried out, the gel slices containing the 
amplified vimentin cDNA fragment were dissolved and then purified. The entire 
process of purification was further divided into three steps according to the 
Promega protocol for Wizard® SV Gel and PCR Clean-Up System, namely 
binding, washing and elution of the gene DNA. 
Firstly, the gel slice was dissolved in the presence of guanidine isothiocyanate, 
contained in the Membrane Binding Solution, and per 10 mg of agarose gel slice 
was added a ratio of 10 μl of solution. This mixture was incubated at 65°C for 10 
minutes or until the gel slice was completely dissolved. For the binging step, the 
dissolved gel mixture was transferred to the SV minicolumn assembly into the 
collection tube and incubated for 1 minute at room temperature. The mixture was 
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then centrifuged at 13,000 rpm for 1 minute, followed by the removal of the flow –
through and the SV minicolumn was reinserted into the collection tube.  
During the washing step, 700 μl of membrane wash solution (containing ethanol) 
was added to the SV minicolumn  to remove all excess components of the reaction 
but the DNA bound to the membrane. The SV minicolumn assembly was 
centrifuged at 13,000 rpm for 1 minute and the flow through was again removed. 
This same procedure was repeated one more time, but with 500 μl of membrane 
wash solution and 5 minutes of centrifugation at 13,000 rpm. To finish off the 
washing of the gene DNA, only the SV Minicolumn was again centrifuged for 
about 1 minute to allow evaporation of any residual ethanol. 
Finally in the elution step, the SV minicolumn was transferred into a new sterile 1.5 
ml eppendorf tube, and incubated at room temperature for 1 minute after the 
addition of 50 μl of nuclease –free water. The minicolumns were then centrifuged at 
13,000 rpm for 1 minute, and the quantification of the purified Vimentin gene was 
carried out using the Nanodrop spectrophotometer. Lastly, the purified Vimentin 
gene was stored at –20° C. 
 
4. Ligation of Vimentin in Topo vector  
The Vimentin ligation in Topo vector was performed according to the Life 
technologies protocol for TOPO® TA Cloning Kit for Sequencing. The cloning 
strategy of this kit was highly efficient and very fast, as it allowed direct insertion of 
the Taq polymerase-PCR products into a plasmid vector. No ligase, post-PCR 
procedures, PCR primers or specific sequences were required. 
The PCR ™ 4-TOPO® vector was a linear plasmid with single 3' thymidine (T) 
overhangs; it also was an "activated" vector being covalently bound to a 
Topoisomerase. As showed in the vector map (Figure 48), the vector also contained 
the genes for resistance to the antibiotics Ampicillin (Amp) and Kanamycin. 
 
Figure 48: Map and sequence for the Topo vector (Invitrogen). 
 
During the PCR reaction, the Taq polymerase adds a single deoxyadenosine (A) to 
the 3' ends of PCR products, due to its non –template –dependent terminal 
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transferase activity. As mentioned above, the linearized vector has single residues 
overhanging 3' deoxythymidine (T) and this has allowed  the PCR inserts to ligate 
efficiently with the vector. 
 
For the ligation reaction, 4 μl of purified Vimentin (obtained with PCR reaction) 
were mixed with 1 μl of salt solution and 1 μl of Topo vector. This mixture was 
incubated at room temperature for 30 minutes. Finally, this reaction was purified 
with butanol and then transformed into Top 10 competent cells.  
 
5. pET-22b(+) vector system  
The pET System is one of the best systems so far developed for the cloning and 
expression of recombinant proteins, such as Vimentin, in the E. coli strain BL 21 
star DE3. 
The pET-22b(+) cloning/expression vector (Novagen) was chosen for the cloning 
and expression of the Vimentin protein for a number of reasons. The pET-22b(+) 
vector is a stable plasmid of about 5.5 kb in size. This vector has the following 
characteristics: a high expression promoter, i.e. the T7 promoter that allowed to 
obtain high expression levels, and the Ap gene, that is responsible for resistance to 
Amp antibiotic. It has also an His Tag, which is very important for purification of 
the Vimentin protein via Nickel column. 
 
 
Figure 49: Map and sequence for the pET-22b(+) cloning/expression vector (Novagen). 
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Initially, 2 µl of the pET pET-22b(+)vector stock was transformed into competent 
cells and then the vector was prepared for the Vimentin ligation (see below 
REdigestion and SAP treatment). 
 
6. DNA precipitation with Butanol 
The Vimentin ligation reaction with Topo (6µl) or pET vector (10 µl) was purified 
through the precipitation with butanol to remove all the components that could 
interfere during the transformation of E. coli competent cells. Reaction was filled 
up to 50 µl with water, then 450ul butanol was added. This mixture was centrifuged 
13000 rpm at 4° C for 10 minutes. The supernatant was removed and any residual 
butanol was evaporated. Finally, the pellet was resuspended in nuclease –free water 
equal to 2 µl for Topo vector or 5 µl of pET vector, respectively. 
 
7. Transformation into competent cells (E. Coli) 
The transformation into competent cells was carried out in order to clone the 
Vimentin gene. The procedure was the same for both vectors according to the 
Invitrogen protocol, except that different types of competent cells were used.  
The TOP10 chemically competent E. coli (Invitrogen) was chosen for the Topo 
vector transformation, because these cells were able to obtain a stable replication of 
high-copy number plasmids. Moreover, they were provided at a transformation 
efficiency of 1 x 109 cfu/µg supercoiled DNA and were ideal for high-efficiency 
cloning and plasmid propagation. 
Instead, the BL21 Star™(DE3) chemically competent cells (Invitrogen) were 
designed for applications that require T7 promoter-based expression systems, i.e. 
the pET-22b(+) vector, and high-level expression of non-toxic recombinant 
proteins. These cells were provided at a transformation efficiency of 1 x 108 cfu/µg 
plasmid DNA. 
Into a vial of competent cells, 2 µl of ligation reaction (after butanol precipitation) 
were added and incubated on ice for 30 minutes. The cells were then heat-shocked 
for 30 seconds at 42°C without shaking and incubated again on ice for 10 minutes. 
Later, 700 µl of S.O.C. medium were added into each vial of competent cells and 
incubated for one hour with shaking. The bacterial suspension was centrifuged at 
3000 rpm for 2 minutes, and 650 µl of supernatant were removed. Finally, 50 µl of 
each suspension was spread onto a selective Luria –Bertani (LB) agar-plate, 
containing Amp, and all the plates where afterwards put into an incubator at 37 °C 
overnight so that the colonies could grow. The negative control was performed to 
verify that there were no other bacterial contaminations. The following day, the 
plates were observed and the isolated colonies were selected. 
 
8. Plasmid extraction of selected clones 
After the transformation into competent cell, selected isolated colonies were added 
in 3 ml of LB broth medium containing Amp, and incubated overnight at 37° C. The 
following day, 1 ml of each bacterial suspension was mixed with glycerol (final 
concentration 20-30%) and stored at -80° C to keep frozen stocks. The remaining 
2ml of the bacterial suspension were used for plasmid extraction according to the 
Promega protocol for Wizard plus SV minipreps DNA purification system kit. The 
Plasmid extraction was divided into four main steps, namely production of cleared 
lysate as well as binding, washing and elution of the vector DNA.  
Firstly, the 1.8 ml of bacterial suspension were centrifuged at 13,000 rpm for 2 
minutes and LB medium was removed. The pellet was then resuspended with 250 
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μl of cell resuspension solution in an eppendorf tube, followed by the addition of 
another 250 μl of cell lysis solution, used to degrade the cells completely. To 
degrade the remaining proteins, 10 μl of alkaline protease solution was added and 
the mixture was incubated for about 5 minutes at room temperature. After this time, 
350 μl of neutralization solution were added and centrifuged at 13,000 rpm for 10 
minutes, and thus all the reactions (lysis or alkaline protease) were stopped. 
In order to start the binding step of the extraction, a spin column was inserted into 
the collection tube and the lysate was transferred into the spin column. The 
assembly was then centrifuged at 13,000 rpm for 1 minute. The flow –through was 
removed and then the spin column was reinserted into the collection tube. 
During the washing step, 750 μl of wash solution (containing ethanol) was added. 
The assembly was centrifuged at 13,000 rpm for 1 minute and the flow –through 
was removed again. This same procedure was repeated one more time, but with 250 
μl of wash solution and 2 minutes of centrifugation at 13,000 rpm.  
Lastly, in order to elute the plasmid DNA, the spin column was transferred to a 1,5 
ml new sterile eppendorf tube. 50 μl of nuclease-free water was added, followed by 
centrifugation at 13,000 rpm for 1 minutes and removal of the spin column. The 
DNA was quantified by the Nanodrop 2000 spectrophotometer and then stored in a 
fridge at –20 °C before further use.  
 
9. Restriction enzyme site digestion analysis 
Restriction enzyme site digestion analysis was performed to identify suitable sites 
that could be used for cloning purposes, i.e. to move the coding sequence of 
Vimentin from the Topo maintenance vector into the pET-22b(+) 
cloning/expression vector. 
In order to do this, two common restriction enzyme sites (i.e. Bam HI and Sal I 
REs) had to be found on both the Vimentin coding sequence, Topo Vector sequence 
and the pET-22b(+) vector sequence.  
 
The restriction site digestion analysis for the Vimentin coding sequencehad 
identified a list of appropriate RE sites, whose enzymes could not cut the Vimentin 
gene (Figure 50).  
 
Non Cut Enzymes 
AatII Acc65I AccIII AclI AflII AgeI 
AhaIII Alw44I ApaBI ApaI ApaLI AscI 
Asp718I AsuII AvrII BalI BamHI BbeI 
BbvII BclI BglI BglII Bpu1102I Bsc91I 
BsiI BsmI Bsp1407I BspHI BspMII BstD102I 
BstEII BstXI Csp45I CspI DraI DraIII 
DrdI Eco31I Eco47III Eco72I EcoRI EcoRV 
EheI EspI FseI HindIII HpaI I-PpoI 
KpnI MfeI Mlu113I MluI MscI MstI 
NarI NcoI NdeI NheI NotI NruI 
NsiI PacI PflMI PinAI PmaCI PmeI 
PvuI PvuII RleAI SacII SalI SapI 
ScaI SfiI SgrAI SnaBI SpeI SphI 
SpoI SspI SstII StuI SwaI VspI 
XbaI XmnI XorII 
Figure 50: RE sites in pET-22b(+) vector. 
List of RE sites indicating which REs that would not cut the Vimentin gene, with two 
possible RE sites, which were also found in the RE list of the pET-22b(+) vector, 
highlighted in red. 
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The recognition sequences of these enzymes are shown in the figure 51 below: 
 
Bam HI: 
5' - G^G A T C C - 3' 
3' - C C T A G^G - 5' 
 
Sal I: 
5' - G^T C G A C - 3' 
3' - C A G C T^G - 5' 
 
Figure 51: The sequence of restriction enzyme site for Bam HI and Sal I enzymes. 
This ^ was indicated of the enzyme cleavage site. 
 
Therefore, a set of primers had to be designed which also contained the Bam HI and 
Sal I RE sequences. The chosen REs would then also be used to cut the pET-22b(+) 
vector open so that the isolated Vimentin sequence could fit in it and ligate to it, in 
order to later clone and express the final Vimentin protein (figure 52).  
 
Figure 52: Sequence and multiple cloning site for the pET-22b(+) cloning/expression vector.  
Tree possible RE sites, which are also found in the Vimentin coding sequence, circled in 
red. 
 
Before the Vimentin ligation, if a double digestion with Bam HI and Sal I was 
performed on the pET-22b(+) vector, the portion of its genome located between 
these enzymes was removed.  
 
For a double site digestion analysis(with Bam HI and Sal I REs), we had prepared 
10 µl of a mixture that contained 5 µl of purified DNA plasmid, 1 µl of Bam HI RE, 
2 µl of Sal I RE, 2 µl of Bam HI Lsp buffer and nuclease –free water. The 
procedure is the same as used for the Eco RI digestion. 
Instead, to isolate and purify the RE digested DNA, a large double digestion with 
Bam HI and Sal I REs was carried out by increasing the concentration of the sample 
and all the reagents. Therefore, 20 µl of purified DNA plasmid, 1,5 µl of Bam HI 
RE, 3 µl of Sal I RE and 3 µl of Bam HI Lsp buffer were incubated at 37° C for 2 
hours and the digestion was made. The products of digestion were separated by 
agarose –gel electrophoresis and the specific DNA band was cut and this gel slice 
was processed with Wizard® SV Gel and PCR Clean-Up System (Promega). 
 
10. SAP Treatment of Restriction Digested DNA 
Shrimp alkaline phosphate (SAP) was used to remove 5'- and 3'-phosphate groups 
from DNA.We used this enzyme to prevent self-ligation of restriction digested pET 
vector DNA before the insertion of Vimentin fragment.  
In order to reach the final volume of 20 μl, a mixture was made with 12 µl 
restriction digested pET vector DNA, 2 µl SAP enzyme and 2 µl 10x SAP buffer 
and nuclease –free water. This reaction was then incubated at 37° C for 1 hour to 
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allow the removal of phosphate groups. After this time, the enzyme was inactivated 
by incubating at 65° C.  
The SAP reaction was then purified according to the Promega protocol of Wizard® 
SV Gel and PCR Clean-up System kit, resuspended in nuclease –free water, then 
quantified using the NanoDrop spectrophotometer and finally it was stored at -20°C 
before further use. 
 
11. Ligation of Vimentin in pET -22b(+) vector 
For the Vimentin / pET -22b(+) vector ligation, the optimal molar ratio between 
them was a 1/3. Therefore, two ligation reactions were carried out. One was a 
standard reaction which contained 6 µl of Vimentin fragment (i.e. purified 
Vimentin 2 was previously extracted by Topo vector), 2 µl of the SAP digested pET 
vector (about 30 ng), 1 µl the T4 Ligase enzyme (which catalyzes the bind between 
insert and vector) and 1 µl of the T4 Ligase buffer (necessary to activate the 
reaction and maintain a stable pH). And another one was a negative control, which 
contained all the reaction components except the Vimentin insert. Both the ligation 
reactions were incubated overnight at 16° C, butanol-precipitated and then were 
transformed into BL 21 (DE3) competent cell. 
 
12. Sequencing electrophoresis analysis 
The sequencing electrophoresis analysis is a technique that allows to verify if the 
fragment sequence (i.e. the Vimentin gene) inserted into the vector is correct. This 
technique was composed of three different phases: an initial PCR reaction, a 
separation by capillary electrophoresis and finally an optical detection. 
This analysis was not possible to carry out in our laboratory. Thus, 10 µl of each 
sample, and 20 µl of each primer were sent off to the Central DNA Sequencing 
Facility laboratory of the University of Stellenbosch where the sequencing 
electrophoresis analysis was performed.  
The sequencing was performed with the vector primers, i.e. M13 reverse and M13 
forward primers for Topo vector samples or T7 promoter and T7 terminator primers 
for pET-22b(+) vector samples, respectively. 
In addition, to be sure to verify with success the entire sequence of Vimentin, two 
internal primers were identified with the NCBI website, named sequence 1 and 2 
respectively, and their aliquots (20 µl) sent out.  
Therefore, the PCR cycle of sequencing required a DNA template, primers, but 
also, a thermal stable DNA polymerase, nucleotides (dNTPs), dideoxynucleotides 
(ddNTPs), and buffer.  These components were combined in a reaction that has 
been subjected to cycles of annealing, extension and denaturation in a 
thermocycler. During this phase, the DNA polymerase had created and amplified 
extension products on the DNA template. The extension of these products was 
terminated when DNA polymerase had inserted one of the four dideoxynucleotides, 
each of which was bound to a specific fluorophore dye. 
Subsequently, using a capillary electrophoresis, the extension products of the PCR 
cycle of sequencing were separated depending to their size, and then were exposed 
to a laser beam, which had stimulated the dideoxynucleotides dyes to emit 
fluorescence. Because each dye emits light at a different wavelength when excited 
by the laser, all four colors, and therefore all four bases, can be detected and 
distinguished by an optical detection [by DNA Sequencing by Capillary 
Electrophoresis, Applied Biosystems Chemistry Guide, Second Edition]. 
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Finally, the instrument is connected to a Software that converted the fluorescence 
signal to digital data, then records the data in a *.ab1 file. The digital data were 
shown in a chromatogram, constituted by a series of peaks of four different colors, 
each corresponding to one dideoxynucleotide. In addition to the chromatogram, the 
software has also supplied the nucleotide sequence, which  could then be analyzed 
with the help of the program DNA Man. 
 
Immunoblotting 
For detection of proteins from MDA-MB-231 cell lysates by immunoblot, standard 
protocols were applied. Cells were seeded in 6-well plates at 2.0 × 105 cells per well 
and incubated overnight in a humidified atmosphere of 5% CO2 at 37◦C. After 
adherence overnight, the culture medium was replaced with fresh medium and the 
cells were treated with 10 µM Z-Z-ajoene in DMSO (0.1% v/v). Control cells received 
DMSO (0.1% v/v) alone. Cells were incubated with Z-Z-ajoene for a total of 24 h. 
Cells were lysed in Lysis buffer 5X (Promega) Total protein was quantified using the 
Pierce BCA protein assay kit (Thermo Fischer Scientific, Life Technologies). For all 
Western blotting, 10 µg of total protein was separated by SDS-PAGE and transferred 
to nitrocellulose membranes. Membranes were blocked for 1 h at room temperature 
using 5% non-fat milk in PBS containing Tween-20 and incubated with the primary 
antibodies overnight at 4°C: anti-AXL, anti- β-catenin, anti- phospho-β-catenin (Ser 
33), anti- E-cadherin, anti- vimentin (V9 and H84) (1:1000) (all Santa Cruz, 
Whitehead Scientific, South Africa); anti-Src (1:1000; Cell Signaling Technology); 
anti-β-tubulin and anti-GAPDH (1:1000) (both Santa Cruz, Whitehead Scientific). 
Specific proteins were detected using appropriate horseradish peroxidase-conjugated 
secondary antibodies and the LumiGLO chemiluminescent reagent (KPL, Biocom 
Biotech, South Africa). A protein ladder (ThermoFischer Scientific, Life 
Technologies) was used to estimate the molecular weight of proteins. 
 
Immunohistochemistry  
MDA-MB-231 cells were seeded on sterile coverslips in six-well plates (1.2 × 105 
cells per well) and cultured in D-MEM (Dulbecco’s Modified Eagle Medium) 
containing 10 % FBS. The following day, cells were treated with 25 µM DP (in DMSO 
0.1 % v/v), for 6 hours. Thereafter, cells were washed with PBS, permeabilized with 
absolute methanol at -20°C for 5 min and fixed in 4% paraformaldehyde 
(Sigma-Aldrich) for 5 min at room temperature. Cell sections were then washed with 
PBS, incubated in blocking solution (1% bovine serum albumin (BSA) in PBS) for 1 
hour at room temperature, and finally incubated with the primary antibodies 
(anti-vimentin: V9 and H84; anti -PDI) diluted in blocking solution (1:100) overnight 
at 4°C in the dark. The following day, cell sections were washed with PBS and 
incubated with the Cy–3 fluorescently –tagged secondary antibodies (anti-mouse for 
V9 and PDI; anti-rabbit for H84, diluted in blocking solution (1:500) for 90 minutes at 
room temperature in the dark. Then, cell sections were washed with PBS and mounted 
using Mowiol 4-88 (Sigma-Aldrich). The sections were stored in the dark at 4°C until 
viewing with confocal microscope (Carl Zeiss). 
109 
 
 
Proteomics 
To perform the analysis of proteomics, purified recombinant Vimentin protein (10µg, 
Prepotech, USA) treated with or without garlic compounds (100 µM DP or ZA) for 30 
minutes at 37°C. All samples were stored at -80°C until a following peptide analysis 
by the Centre for proteomics and Genomics research (CPGR), Cape Town, South 
Africa. The proteomic analysis is a sensitive analytical technique which allows 
proteins to be analysed by mass spectrometry. Briefly, the protein is first subjected to 
enzymatic digestion by the trypsin. This protease cleaves the protein at the level of the 
C-terminal after the amino acid lysine and arginine; except in the case where these 
residues are followed by a proline. In this way,  protein fragment mixture is formed, 
and then peptides are separated by liquid chromatography that it is coupled to mass 
spectrometry analysis that enables a identification of each fragment. 
 
SiRNA transfection  
MDA-MB-231 cells were seeded on a 6-well plates at 1.0 × 105 cells per well and 
cultured in DMEM (Dulbecco’s Modified Eagle Medium) containing 10 % FBS and 
allowed to settle overnight. The cells were then transfected with 50 or 100 nM 
Vimentin SiRNA (25µM Stock), using Lipofectamide RNAi MAX Reagent 
(Invitrogen) according to the manufacturer’s instruction. After 6 h, medium containing 
the transfection mixture was replaced by fresh culture medium containing 10 % FBS 
and the cells were incubated in a humidified atmosphere of 5 % CO2 at 37◦C for 24, 48 
and 72 h. Cells were lysed in Lysis buffer 5X (Promega). Total protein was quantified 
using the Pierce BCA protein assay kit (Thermo Fischer Scientific, Life 
Technologies). Lysates were stored at -20°C until required. 
 
Wound healing assay  
MDA-MB-231 cells were seeded in 6-well plates at 3.0 × 105 cells per well and 
cultured in DMEM (Dulbecco’s Modified Eagle Medium) containing 10 % FBS to 90 
% confluence. The cell monolayer was carefully wounded using a yellow pipette tip, 
and cellular debris were removed by washing twice with PBS and finally with DMEM. 
The wounded monolayer was incubated with or without ZA (10 µM) for 24 h in 
DMEM containing 1 % (control) and 10 % FBS (positive control, chemoattractant). 
Cell migration into the wound area was monitored and photographed immediately 
after wound formation and then after 24 h, using a phase contrast inverted microscope 
(Olympus CKH41). The degree of wound closure was then quantitatively evaluated by 
ImageJ software and four fields per well were documented. Each experiment was 
performed in triplicate. 
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